Common use of Observer Rights Clause in Contracts

Observer Rights. (a) As long as any shares of Preferred Stock are outstanding (as adjusted for stock splits, stock combinations, stock dividends and the like), the Company shall invite a representative of Collage Venture Partners, LLC, a Florida limited liability company (the “Placement Agent”), initially ▇▇▇▇▇▇ ▇▇▇▇▇▇▇, to attend all meetings of the Board of Directors in a nonvoting observer capacity and, in this respect, shall give such representative copies of all notices, minutes, consents, and other materials that it provides to the Board of Directors; provided, however, that such representative shall agree to hold in confidence all information so provided; and provided further, that the Company reserves the right to withhold any information and to exclude such representative from any meeting or portion thereof if access to such information or attendance at such meeting would be reasonably likely to adversely affect the attorney-client privilege between the Company and its counsel, result in disclosure of trade secrets or highly confidential information, create a competitive harm or competitive disadvantage, or relates to subject matter in which the Placement Agent may have a conflict of interest, or if the Placement Agent or its representative is a Competitor. (b) In the event that ▇.▇. ▇▇▇▇▇▇▇ (“▇▇. ▇▇▇▇▇▇▇”) is not elected to the Board as the Series B Director (as defined in the Voting Agreement) and so long as Transhuman Capital, LLC, a Delaware limited liability company (“Transhuman”) and CRS Capital, LLC, a Michigan limited liability company (“CRS”), together with their Affiliates, own at least 1,000,000 shares of Series B Preferred Stock purchased under the Purchase Agreement (as adjusted for stock splits, stock combinations, stock dividends and the like), the Company shall invite ▇▇. ▇▇▇▇▇▇▇ to attend all meetings of the Board of Directors in a nonvoting observer capacity and, in this respect, shall give such representative copies of all notices, minutes, consents, and other materials that it provides to the Board of Directors; provided, however, that such representative shall agree to hold in confidence all information so provided; and provided further, that the Company reserves the right to withhold any information and to exclude such representative from any meeting or portion thereof if access to such information or attendance at such meeting would be reasonably likely to adversely affect the attorney-client privilege between the Company and its counsel, result in disclosure of trade secrets or highly confidential information, create a competitive harm or competitive disadvantage, or relates to subject matter in which Transhuman or CRS may have a conflict of interest, or if Transhuman, CRS or their representative is a Competitor.

Appears in 2 contracts

Sources: Investors’ Rights Agreement (Retension Pharmaceuticals, Inc.), Investors’ Rights Agreement (Retension Pharmaceuticals, Inc.)

Observer Rights. (a) As long Prior to an Initial Public Offering, Collateral Agent shall have the right to have a single representative attend all meetings of the Board, as any shares of Preferred Stock are outstanding (as adjusted for stock splits, stock combinations, stock dividends and an observer without the like), the Company shall invite a representative of Collage Venture Partners, LLC, a Florida limited liability company right to vote (the “Placement AgentObserver”). Initially, initially ▇▇the Observer shall be ▇▇▇▇ ▇▇▇▇▇▇▇, to attend . Observer shall be provided written notice (which may be via email) of all regular or special meetings of the Board of Directors in a nonvoting observer capacity and, in this respect, at the same time as provided to all directors. Parent shall give such representative concurrently provide Observer with copies of all notices, minutes, consents, consents and other materials that it provides to any member of the Board of Directors; providedor any committee thereof, however, provided that such representative shall agree to hold in confidence all information so provided; and provided further, that the Company reserves the right to withhold any information and to exclude such representative materials protected from any meeting or portion thereof if access to such information or attendance at such meeting would be reasonably likely to adversely affect discovery by the attorney-client privilege between or the Company and its counselattorney work product privilege, result any materials necessary or advisable in disclosure the good faith determination of trade secrets or highly confidential information, create a competitive harm or competitive disadvantage, or relates the Board to subject matter in which the Placement Agent may have avoid a conflict of interestinterest between Borrowers, or if on the Placement Agent or its representative is a Competitorone hand, and Agents and Lenders, on the other hand, confidential compensation information and any trade secrets may be excluded. All Confidential Information provided to Observer pursuant to this Section 5.12 shall be subject to the confidentiality obligations under Section 13.11. (b) In addition to any other rights or remedies to which the event Collateral Agent may be entitled, Borrower agrees to and will indemnify and hold harmless Agents, Lenders, Observer, their Affiliates and all of their respective successors, assigns, officers, directors, employees, attorneys, and agents from and against any and all losses, claims, obligations, liabilities, deficiencies, diminutions in value, penalties, causes of action, damages, costs, and expenses (including, without limitation, costs of investigation and defense, reasonable attorneys' fees and expenses) that ▇.▇. ▇▇▇▇▇▇▇ (they, or any of them, may suffer, incur, or be responsible for, arising or resulting from the exercise of rights pursuant to Section 5.12(a) and/or service or status as an “▇▇. ▇▇▇▇▇▇▇Observer”) is ; provided that Borrower will not elected be required to the Board as the Series B Director (as defined reimburse Observer for out-of-pocket expenses incurred by Observer in the Voting Agreement) and so long as Transhuman Capital, LLC, a Delaware limited liability company (“Transhuman”) and CRS Capital, LLC, a Michigan limited liability company (“CRS”), together connection with their Affiliates, own Observer’s attendance at least 1,000,000 shares of Series B Preferred Stock purchased under the Purchase Agreement (as adjusted for stock splits, stock combinations, stock dividends and the like), the Company shall invite ▇▇. ▇▇▇▇▇▇▇ to attend all any meetings of the Board of Directors in a nonvoting observer capacity and, in this respect, shall give such representative copies of all notices, minutes, consents, and other materials that it provides to the Board of Directors; provided, however, that such representative shall agree to hold in confidence all information so provided; and provided further, that the Company reserves the right to withhold any information and to exclude such representative from any meeting or portion thereof if access to such information or attendance at such meeting would be reasonably likely to adversely affect the attorney-client privilege between the Company and its counsel, result in disclosure of trade secrets or highly confidential information, create a competitive harm or competitive disadvantage, or relates to subject matter in which Transhuman or CRS may have a conflict of interest, or if Transhuman, CRS or their representative is a CompetitorParent’s Board.

Appears in 2 contracts

Sources: Loan and Security Agreement (Domo, Inc.), Loan and Security Agreement (Domo, Inc.)

Observer Rights. (a) As For so long as any SoftBank owns at least 1,667,205 shares of Preferred Stock are outstanding (as adjusted for stock splits, stock dividends, combinations, stock dividends and recapitalizations or the like)) or an equivalent amount of Common Stock issued upon conversion thereof, the Company shall invite a representative of Collage Venture Partners, LLCSoftBank (each such representative, a Florida limited liability company (the “Placement AgentSoftBank Board Observer”), who shall initially ▇be ▇▇▇▇▇ ▇▇▇▇▇▇▇, to attend all meetings of the its Board of Directors in a nonvoting observer capacity and, in this respect, shall give such representative copies of all notices, minutes, consents, consents and other materials that it provides to the Board of Directorsits directors; provided, however, that such representative shall agree to hold in confidence all information so provided; and provided further, that the Company reserves the right to withhold any information and to exclude such representative from any meeting or portion thereof if access to such information or attendance at such meeting (a) would be reasonably likely to adversely affect the attorney-client privilege between the Company and its counsel, counsel or (b) would result in disclosure of trade secrets to such representative or highly confidential information, create a competitive harm or competitive disadvantage, or relates to subject matter in which the Placement Agent may have a conflict of interest, or if . Any SoftBank Board Observer shall be required to enter into a confidentiality agreement with the Placement Agent or its representative is a CompetitorCompany prior to the exercise of the rights contained in this Section 3.6(a). (b) In the event that ▇.▇. ▇▇▇▇▇▇▇ (“▇▇. ▇▇▇▇▇▇▇”) is not elected to the Board as the Series B Director (as defined in the Voting Agreement) and For so long as Transhuman Capital, LLC, a Delaware limited liability company (“Transhuman”) and CRS Capital, LLC, a Michigan limited liability company (“CRS”), together with their Affiliates, own QIA owns at least 1,000,000 250,000 shares of Series B Preferred Stock purchased under the Purchase Agreement (as adjusted for stock splits, stock dividends, combinations, stock dividends and recapitalizations or the like)) or an equivalent amount of Common Stock issued upon conversion thereof, the Company shall invite ▇▇. ▇▇▇▇▇▇▇ a representative of QIA (each such representative, a “QIA Board Observer”), to attend all meetings of the its Board of Directors in a nonvoting observer capacity and, in this respect, shall give such representative copies of all notices, minutes, consents, consents and other materials that it provides to the Board of Directorsits directors; provided, however, that such representative shall agree to hold in confidence all information so provided; and provided further, that the Company reserves the right to withhold any information or portion thereof and to exclude such representative from any meeting or portion thereof if access to such information or attendance at such meeting (a) would be reasonably likely to adversely affect the attorney-client privilege between the Company and its counsel, counsel or (b) would result in disclosure of trade secrets or highly confidential information, create a competitive harm or competitive disadvantage, or relates to subject matter in which Transhuman or CRS may have such representative (c) would represent a conflict of interest, interest or if Transhuman, CRS or their representative is (d) would result in the disclosure of sensitive personal information of U.S. Persons. Any QIA Board Observer shall be required to enter into a Competitorreasonable and customary confidentiality agreement with the Company prior to the exercise of the rights contained in this Section 3.6(b).

Appears in 2 contracts

Sources: Investors’ Rights Agreement (Compass, Inc.), Investors’ Rights Agreement (Urban Compass, Inc.)

Observer Rights. (a) As long as In lieu of appointing any shares of Preferred Stock are outstanding (as adjusted for stock splits, stock combinations, stock dividends and EDH Holder Company Designee to the like)Board, the Company shall invite EDH Holder may appoint a representative of Collage Venture Partners, LLC, a Florida limited liability company the EDH Holder chosen by the EDH Holder in its sole discretion (the “Placement AgentBoard Observer”), initially ▇▇▇▇▇▇ ▇▇▇▇▇▇▇, ) to attend all meetings of the Board of Directors and all committees thereof (whether in person, telephonic or other) in a nonvoting non-voting, observer capacity andcapacity, and in this respect, respect the Company shall give such representative provide to the Board Observer complete copies of all notices, minutes, consents, consents and other materials that it provides are sent to the members of the Board of Directorsor any committee thereof, at the same time such notices, minutes, consents and other materials are provided to the Company’s directors; provided, however, that such representative Board Observer shall agree to hold in confidence and trust all information so provided; and provided further, further that the Company reserves the right to withhold any information and to exclude such representative Board Observer from any meeting or portion thereof if access to such information or attendance at such meeting would be reasonably likely to could adversely affect the attorney-client privilege between the Company and its counsel, counsel or result in disclosure of trade secrets or highly confidential information, create a competitive harm or competitive disadvantage, or relates to subject matter in which the Placement Agent may have a conflict of interest, or if the Placement Agent or its representative is a Competitor. (b) In lieu of appointing any EDH Holder Subsidiary Designee to the event that ▇.▇. ▇▇▇▇▇▇▇ governing body of any Subsidiary of the Company, the EDH Holder may appoint a representative of the EDH Holder chosen by the EDH Holder in its sole discretion (in each case, a “▇▇. ▇▇▇▇▇▇▇Subsidiary Observer”) is not elected to the Board as the Series B Director (as defined in the Voting Agreement) and so long as Transhuman Capital, LLC, a Delaware limited liability company (“Transhuman”) and CRS Capital, LLC, a Michigan limited liability company (“CRS”), together with their Affiliates, own at least 1,000,000 shares of Series B Preferred Stock purchased under the Purchase Agreement (as adjusted for stock splits, stock combinations, stock dividends and the like), the Company shall invite ▇▇. ▇▇▇▇▇▇▇ to attend all meetings of the Board governing body of Directors any Subsidiary of the Company and all committees thereof (whether in person, telephonic or other) in a nonvoting non-voting, observer capacity andcapacity, and in this respect, respect such Subsidiary of the Company shall give such representative provide to the Subsidiary Observer complete copies of all notices, minutes, consents, consents and other materials that it provides are sent to the Board members of Directorsthe governing body of such Subsidiary of the Company or any committee thereof, at the same time such notices, minutes, consents and other materials are provided to such to the members of such Subsidiary’s governing body; provided, however, that such representative Subsidiary Observer shall agree to hold in confidence and trust all information so provided; and provided further, further that the Company reserves the right to withhold any information and to exclude such representative Subsidiary Observer from any meeting or portion thereof if access to such information or attendance at such meeting would be reasonably likely to could adversely affect the attorney-client privilege between the Company such Subsidiary and its counsel, counsel or result in disclosure of trade secrets or highly confidential information, create a competitive harm or competitive disadvantage, or relates to subject matter in which Transhuman or CRS may have a conflict of interest, or if Transhuman, CRS or their representative is a Competitor.

Appears in 2 contracts

Sources: Stock Purchase Agreement (Gsi Commerce Inc), Stock Purchase Agreement (Gsi Commerce Inc)

Observer Rights. (a) As long as Accel XI L.P. and its affiliated funds (“Accel”) hold at least 1,000,000 Shares (appropriately adjusted for any shares stock split, dividend, combination or other recapitalization) of Series C Preferred Stock are outstanding (as adjusted for stock splits, stock combinations, stock dividends and the likeor an equivalent amount of Common Stock issued upon conversion thereof), the Company shall invite a representative of Collage Venture Partners, LLC, a Florida limited liability company (the “Placement Agent”), initially ▇▇▇▇▇▇ ▇▇▇▇▇▇▇, Accel to attend all meetings of the its Board of Directors in a nonvoting observer capacity and, in this respect, shall give such representative copies of all notices, minutes, consents, consents and other materials that it provides to the Board of Directorsits directors; provided, however, that such representative shall agree to hold in confidence and trust and to act in a fiduciary manner with respect to all information so provided; and and, provided further, that the Company reserves the right to withhold any information and to exclude such representative from any meeting or portion thereof if access to such information or attendance at such meeting would be reasonably likely to could adversely affect the attorney-client privilege between the Company and its counsel, counsel or would result in disclosure of trade secrets or highly confidential information, create a competitive harm or competitive disadvantage, or relates to subject matter in which the Placement Agent may have a conflict of interest, such representative or if the Placement Agent or its such representative is a Competitormember of the board of directors of a direct competitor of the Company. (b) In the event that ▇.▇. ▇▇▇▇▇▇▇ As long as Sequoia Capital U.S. Growth Fund VI, L.P. and its affiliated funds (“▇▇. ▇▇▇▇▇▇▇Sequoia”) is not elected to the Board as the Series B Director (as defined in the Voting Agreement) and so long as Transhuman Capital, LLC, a Delaware limited liability company (“Transhuman”) and CRS Capital, LLC, a Michigan limited liability company (“CRS”), together with their Affiliates, own hold at least 1,000,000 shares Shares (appropriately adjusted for any stock split, dividend, combination or other recapitalization) of Series B D Preferred Stock purchased under the Purchase Agreement (as adjusted for stock splits, stock combinations, stock dividends and the likeor an equivalent amount of Common Stock issued upon conversion thereof), the Company shall invite ▇▇. ▇▇▇▇▇▇▇ a representative of Sequoia to attend all meetings of the its Board of Directors in a nonvoting observer capacity and, in this respect, shall give such representative copies of all notices, minutes, consents, consents and other materials that it provides to the Board of Directorsits directors; provided, however, that such representative shall agree to hold in confidence and trust and to act in a fiduciary manner with respect to all information so provided; and and, provided further, that the Company reserves the right to withhold any information and to exclude such representative from any meeting or portion thereof if access to such information or attendance at such meeting would be reasonably likely to could adversely affect the attorney-client privilege between the Company and its counsel, counsel or would result in disclosure of trade secrets or highly confidential information, create a competitive harm or competitive disadvantage, or relates to subject matter in which Transhuman or CRS may have a conflict of interest, such representative or if Transhuman, CRS or their such representative is a Competitormember of the board of directors of a direct competitor of the Company. (c) As long as ▇▇▇ ▇▇▇▇▇▇ ▇▇▇▇, ▇.▇. and its affiliated funds (“DFJ”) hold at least 1,000,000 Shares (appropriately adjusted for any stock split, dividend, combination or other recapitalization) of Series E Preferred Stock (or an equivalent amount of Common Stock issued upon conversion thereof), the Company shall invite a representative of DFJ to attend all meetings of its Board in a nonvoting observer capacity and, in this respect, shall give such representative copies of all notices, minutes, consents and other materials that it provides to its directors; provided, however, that such representative shall agree to hold in confidence and trust and to act in a fiduciary manner with respect to all information so provided; and, provided further, that the Company reserves the right to withhold any information and to exclude such representative from any meeting or portion thereof if, access to such information or attendance at such meeting could adversely affect the attorney-client privilege between the Company and its counsel or would result in disclosure of trade secrets to such representative or if such representative is a member of the board of directors of a direct competitor of the Company. (d) As long as Institutional Venture Partners XV, L.P. and its affiliated funds (“IVP”) hold at least 1,000,000 Shares (appropriately adjusted for any stock split, dividend, combination or other recapitalization) of Series E Preferred Stock (or an equivalent amount of Common Stock issued upon conversion thereof), the Company shall invite a representative of IVP to attend all meetings of its Board in a nonvoting observer capacity and, in this respect, shall give such representative copies of all notices, minutes, consents and other materials that it provides to its directors; provided, however, that such representative shall agree to hold in confidence and trust and to act in a fiduciary manner with respect to all information so provided; and, provided further, that the Company reserves the right to withhold any information and to exclude such representative from any meeting or portion thereof if, access to such information or attendance at such meeting could adversely affect the attorney-client privilege between the Company and its counsel or would result in disclosure of trade secrets to such representative or if such representative is a member of the board of directors of a direct competitor of the Company. (e) As long as Sapphire Ventures Fund II, L.P. and its affiliated funds (“Sapphire”) hold at least 1,000,000 Shares (appropriately adjusted for any stock split, dividend, combination or other recapitalization) of Series F Preferred Stock (or an equivalent amount of Common Stock issued upon conversion thereof), the Company shall invite a representative of Sapphire to attend all meetings of its Board in a nonvoting observer capacity and, in this respect, shall give such representative copies of all notices, minutes, consents and other materials that it provides to its directors; provided, however, that such representative shall agree to hold in confidence and trust and to act in a fiduciary manner with respect to all information so provided; and, provided further, that the Company reserves the right to withhold any information and to exclude such representative from any meeting or portion thereof if, access to such information or attendance at such meeting could adversely affect the attorney-client privilege between the Company and its counsel or would result in disclosure of trade secrets to such representative or if such representative is a member of the board of directors of a direct competitor of the Company. It is agreed that Sapphire and its Affiliates shall not be deemed a “direct competitor” of the Company for purposes of this Section 2.10(e).

Appears in 2 contracts

Sources: Investors’ Rights Agreement (Sumo Logic, Inc.), Investors’ Rights Agreement (Sumo Logic, Inc.)

Observer Rights. (a) As long as any KPCB Holdings, Inc., as nominee (“KPCB”) owns not less than 1,000,000 shares of the Series A Preferred Stock are outstanding (as adjusted for stock splits, stock combinations, stock dividends and the likeor an equivalent amount of Common Stock issued upon conversion thereof), the Company shall invite a representative of Collage Venture Partners, LLC, a Florida limited liability company (the “Placement Agent”), initially ▇▇▇▇▇▇ ▇▇▇▇▇▇▇, KPCB to attend all meetings of the its Board of Directors in a nonvoting observer capacity and, in this respect, shall give such representative copies of all notices, minutes, consents, and other materials that it provides to the Board of Directorsits directors; provided, however, that such representative shall agree to hold in confidence and trust and to act in a fiduciary manner with respect to all information so provided; and provided further, that the Company reserves the right to withhold any information and to exclude such representative from any meeting or portion thereof if access to such information or attendance at such meeting would be reasonably likely to could adversely affect the attorney-client privilege between the Company and its counsel, counsel or result in disclosure of trade secrets or highly confidential information, create a competitive harm or competitive disadvantage, or relates to subject matter in which the Placement Agent may have a conflict of interest, or if the Placement Agent such Investor or its representative is a Competitorcompetitor of the Company. (b) In the event that ▇.▇. ▇▇▇▇▇▇▇ As long as Obvious Group LLC (“▇▇. ▇▇▇▇▇▇▇Obvious”) is owns not elected to the Board as the Series B Director (as defined in the Voting Agreement) and so long as Transhuman Capital, LLC, a Delaware limited liability company (“Transhuman”) and CRS Capital, LLC, a Michigan limited liability company (“CRS”), together with their Affiliates, own at least 1,000,000 less than 1,400,000 shares of the Series B Preferred Stock purchased under the Purchase Agreement (as adjusted for stock splits, stock combinations, stock dividends and the likeor an equivalent amount of Common Stock issued upon conversion thereof), the Company shall invite ▇▇. ▇▇▇▇▇▇▇ a representative of The Obvious Corporation or its Affiliates to attend all meetings of the its Board of Directors in a nonvoting observer capacity and, in this respect, shall give such representative copies of all notices, minutes, consents, and other materials that it provides to the Board of Directorsits directors; provided, however, that such representative shall agree to hold in confidence and trust and to act in a fiduciary manner with respect to all information so provided; and provided further, that the Company reserves the right to withhold any information and to exclude such representative from any meeting or portion thereof if access to such information or attendance at such meeting would be reasonably likely to could adversely affect the attorney-client privilege between the Company and its counsel, counsel or result in disclosure of trade secrets or highly confidential information, create a competitive harm or competitive disadvantage, or relates to subject matter in which Transhuman or CRS may have a conflict of interest, or if Transhuman, CRS such Investor or their its representative is a Competitorcompetitor of the Company. (c) As long as Gates Ventures, LLC (“GV”) owns not less than 650,000 shares of the Series C Preferred Stock (or an equivalent amount of Common Stock issued upon conversion thereof), the Company shall invite a representative of GV or its Affiliates to attend all meetings of its Board in a nonvoting observer capacity and, in this respect, shall give such representative copies of all notices, minutes, consents, and other materials that it provides to its directors; provided, however, that such representative shall agree to hold in confidence and trust and to act in a fiduciary manner with respect to all information so provided; and provided further, that the Company reserves the right to withhold any information and to exclude such representative from any meeting or portion thereof if access to such information or attendance at such meeting could adversely affect the attorney-client privilege between the Company and its counsel or result in disclosure of trade secrets or a conflict of interest, or if such Investor or its representative is a competitor of the Company. (d) As long as Tsai or its Affiliates own not less than 1,200,000 shares of the Series D Preferred Stock (or an equivalent amount of Common Stock issued upon conversion thereof), the Company shall invite a representative of Tsai to attend all meetings of its Board in a nonvoting observer capacity and, in this respect, shall give such representative copies of all notices, minutes, consents, and other materials that it provides to its directors; provided, however, that such representative shall agree to hold in confidence and trust and to act in a fiduciary manner with respect to all information so provided; and provided further, that the Company reserves the right to withhold any information and to exclude such representative from any meeting or portion thereof if access to such information or attendance at such meeting could adversely affect the attorney-client privilege between the Company and its counsel or result in disclosure of trade secrets or a conflict of interest, or if such Investor or its representative is a competitor of the Company. (e) As long as S2G or its Affiliates own not less than 860,000 shares of the Series D Preferred Stock (or an equivalent amount of Common Stock issued upon conversion thereof), the Company shall invite a representative of S2G to attend all meetings of its Board in a nonvoting observer capacity and, in this respect, shall give such representative copies of all notices, minutes, consents, and other materials that it provides to its directors; provided, however, that such representative shall agree to hold in confidence and trust and to act in a fiduciary manner with respect to all information so provided; and provided further, that the Company reserves the right to withhold any information and to exclude such representative from any meeting or portion thereof if access to such information or attendance at such meeting could adversely affect the attorney-client privilege between the Company and its counsel or result in disclosure of trade secrets or a conflict of interest, or if such Investor or its representative is a competitor of the Company. (f) As long as Union Grove and its Affiliates own not less than 500,000 shares of Preferred Stock (or an equivalent amount of Common Stock issued upon conversion thereof), if a representative of Union Grove is not then serving on the Board, then the Company shall invite a representative of Union Grove to attend all meetings of its Board in a nonvoting observer capacity and, in this respect, shall give such representative copies of all notices, minutes, consents, and other materials that it provides to its directors; provided, however, that such representative shall agree to hold in confidence and trust and to act in a fiduciary manner with respect to all information so provided; and provided further, that the Company reserves the right to withhold any information and to exclude such representative from any meeting or portion thereof if access to such information or attendance at such meeting could adversely affect the attorney-client privilege between the Company and its counsel or result in disclosure of trade secrets or a conflict of interest, or if such Investor or its representative is a competitor of the Company. (g) As long as Tyson owns not less than 1,800,000 shares of the Series F Preferred Stock (or an equivalent amount of Common Stock issued upon conversion thereof), the Company shall invite a representative of Tyson to attend all meetings of its Board in a nonvoting observer capacity and, in this respect, shall give such representative copies of all notices, minutes, consents, and other materials that it provides to its directors; provided, however, that such representative shall agree to hold in confidence and trust and to act in a fiduciary manner with respect to all information so provided; and provided further, that the Company reserves the right to withhold any information and to exclude such representative from any meeting or portion thereof if access to such information or attendance at such meeting could adversely affect the attorney-client privilege between the Company and its counsel or result in disclosure of trade secrets or a conflict of interest. (h) As long as Innovative Fund, LLC (“Future Foods”) and its Affiliates own not less than 800,000 shares of Preferred Stock (or an equivalent amount of Common Stock issued upon conversion thereof), the Company shall invite a representative of Future Foods to attend all meetings of its Board in a nonvoting observer capacity and, in this respect, shall give such representative copies of all notices, minutes, consents, and other materials that it provides to its directors; provided, however, that such representative shall agree to hold in confidence and trust and to act in a fiduciary manner with respect to all information so provided; and provided further, that the Company reserves the right to withhold any information and to exclude such representative from any meeting or portion thereof if access to such information or attendance at such meeting could adversely affect the attorney-client privilege between the Company and its counsel or result in disclosure of trade secrets or a conflict of interest. (i) As long as Mitsui & Co. (U.S.A.), Inc. (“Mitsui”) and its Affiliates own not less than 400,000 shares of the Series F Preferred Stock (or an equivalent amount of Common Stock issued upon conversion thereof), the Company shall invite a representative of Mitsui to attend all meetings of its Board in a nonvoting observer capacity and, in this respect, shall give such representative copies of all notices, minutes, consents, and other materials that it provides to its directors; provided, however, that such representative shall agree to hold in confidence and trust and to act in a fiduciary manner with respect to all information so provided; and provided further, that the Company reserves the right to withhold any information and to exclude such representative from any meeting or portion thereof if access to such information or attendance at such meeting could adversely affect the attorney-client privilege between the Company and its counsel or result in disclosure of trade secrets or a conflict of interest. (j) As long as Cleveland Avenue, LLC (“Cleveland Avenue”) and its Affiliates own not less than 800,000 shares of Preferred Stock (or an equivalent amount of Common Stock issued upon conversion thereof), the Company shall invite a representative of Cleveland Avenue to attend all meetings of its Board in a nonvoting observer capacity and, in this respect, shall give such representative copies of all notices, minutes, consents, and other materials that it provides to its directors; provided, however, that such representative shall agree to hold in confidence and trust and to act in a fiduciary manner with respect to all information so provided; and provided further, that the Company reserves the right to withhold any information and to exclude such representative from any meeting or portion thereof if access to such information or attendance at such meeting could adversely affect the attorney-client privilege between the Company and its counsel or result in disclosure of trade secrets or a conflict of interest.

Appears in 2 contracts

Sources: Investors’ Rights Agreement (Beyond Meat, Inc.), Investors’ Rights Agreement (Beyond Meat, Inc.)

Observer Rights. (a) As long as any shares of Preferred Stock are outstanding Aisling Capital IV, LP (as adjusted for stock splits, stock combinations, stock dividends and the like)“Aisling”) is a Major Investor, the Company shall invite a representative of Collage Venture Partners, LLC, a Florida limited liability company (the “Placement Agent”), initially ▇▇▇▇▇▇ ▇▇▇▇▇▇▇, Aisling to attend all meetings of the Board of Directors in a nonvoting observer capacity and, in this respect, shall give such representative copies of all notices, minutes, consents, and other materials that it provides to its directors at the Board of Directorssame time and in the same manner as provided to such directors; provided, however, that such representative shall agree to hold in confidence and trust and to act in a fiduciary manner with respect to all information so provided; and provided further, that the Company reserves the right to withhold any information and to exclude such representative from any meeting or portion thereof if access to such information or attendance at such meeting would be reasonably likely to could adversely affect the attorney-client privilege between the Company and its counsel, counsel or result in disclosure of trade secrets or highly confidential information, create a competitive harm or competitive disadvantage, or relates to subject matter in which the Placement Agent may have a conflict of interest, or if the Placement Agent such Investor or its representative is a Competitorcompetitor of the Company. (b) In the event that ▇.▇As long as Vertex Global HC Fund II Pte. ▇▇▇▇▇▇▇ Ltd. (“▇▇. ▇▇▇▇▇▇▇Vertex”) is not elected to the Board as the Series B Director (as defined in the Voting Agreement) and so long as Transhuman Capital, LLC, a Delaware limited liability company (“Transhuman”) and CRS Capital, LLC, a Michigan limited liability company (“CRS”), together with their Affiliates, own at least 1,000,000 shares of Series B Preferred Stock purchased under the Purchase Agreement (as adjusted for stock splits, stock combinations, stock dividends and the like)Major Investor, the Company shall invite ▇▇. ▇▇▇▇▇▇▇ a representative of Vertex to attend all meetings of the Board of Directors in a nonvoting observer capacity and, in this respect, shall give such representative copies of all notices, minutes, consents, and other materials that it provides to its directors at the Board of Directorssame time and in the same manner as provided to such directors; provided, however, that such representative shall agree to hold in confidence and trust and to act in a fiduciary manner with respect to all information so provided; and provided further, that the Company reserves the right to withhold any information and to exclude such representative from any meeting or portion thereof if access to such information or attendance at such meeting would be reasonably likely to could adversely affect the attorney-client privilege between the Company and its counsel, counsel or result in disclosure of trade secrets or highly confidential information, create a competitive harm or competitive disadvantage, or relates to subject matter in which Transhuman or CRS may have a conflict of interest, or if Transhuman, CRS such Investor or their its representative is a Competitorcompetitor of the Company. (c) As long as BVF Partners L.P. (“BVF”) is a Major Investor, the Company shall invite a representative of BVF to attend all meetings of the Board in a nonvoting observer capacity and, in this respect, shall give such representative copies of all notices, minutes, consents, and other materials that it provides to its directors at the same time and in the same manner as provided to such directors; provided, however, that such representative shall agree to hold in confidence and trust and to act in a fiduciary manner with respect to all information so provided; and provided further, that the Company reserves the right to withhold any information and to exclude such representative from any meeting or portion thereof if access to such information or attendance at such meeting could adversely affect the attorney-client privilege between the Company and its counsel or result in disclosure of trade secrets or a conflict of interest, or if such Investor or its representative is a competitor of the Company. (d) As long as Qiming U.S. Healthcare Fund II, L.P. (“Qiming”) is a Major Investor, the Company shall invite a representative of Qiming to attend all meetings of the Board in a nonvoting observer capacity and, in this respect, shall give such representative copies of all notices, minutes, consents, and other materials that it provides to its directors at the same time and in the same manner as provided to such directors; provided, however, that such representative shall agree to hold in confidence and trust and to act in a fiduciary manner with respect to all information so provided; and provided further, that the Company reserves the right to withhold any information and to exclude such representative from any meeting or portion thereof if access to such information or attendance at such meeting could adversely affect the attorney-client privilege between the Company and its counsel or result in disclosure of trade secrets or a conflict of interest, or if such Investor or its representative is a competitor of the Company. (e) As long as any Affiliate of Driehaus Capital Management LLC (“Driehaus”) is a Major Investor, the Company shall invite a representative of Driehaus to attend all meetings of the Board in a nonvoting observer capacity and, in this respect, shall give such representative copies of all notices, minutes, consents, and other materials that it provides to its directors at the same time and in the same manner as provided to such directors; provided, however, that such representative shall agree to hold in confidence and trust and to act in a fiduciary manner with respect to all information so provided; and provided further, that the Company reserves the right to withhold any information and to exclude such representative from any meeting or portion thereof if access to such information or attendance at such meeting could adversely affect the attorney-client privilege between the Company and its counsel or result in disclosure of trade secrets or a conflict of interest, or if such Investor or its representative is a competitor of the Company. (f) As long as venBio is a Major Investor, the Company shall invite a representative of venBio to attend all meetings of the Board in a nonvoting observer capacity and, in this respect, shall give such representative copies of all notices, minutes, consents, and other materials that it provides to its directors at the same time and in the same manner as provided to such directors; provided, however, that such representative shall agree to hold in confidence and trust and to act in a fiduciary manner with respect to all information so provided; and provided further, that the Company reserves the right to withhold any information and to exclude such representative from any meeting or portion thereof if access to such information or attendance at such meeting could adversely affect the attorney-client privilege between the Company and its counsel or result in disclosure of trade secrets or a conflict of interest, or if such Investor or its representative is a competitor of the Company. (g) As long as Boxer Capital, LLC (“Boxer”) is a Major Investor, the Company shall invite a representative of Boxer to attend all meetings of the Board in a nonvoting observer capacity and, in this respect, shall give such representative copies of all notices, minutes, consents, and other materials that it provides to its directors at the same time and in the same manner as provided to such directors; provided, however, that such representative shall agree to hold in confidence and trust and to act in a fiduciary manner with respect to all information so provided; and provided further, that the Company reserves the right to withhold any information and to exclude such representative from any meeting or portion thereof if access to such information or attendance at such meeting could adversely affect the attorney-client privilege between the Company and its counsel or result in disclosure of trade secrets or a conflict of interest, or if such Investor or its representative is a competitor of the Company.

Appears in 2 contracts

Sources: Investors’ Rights Agreement (Elevation Oncology, Inc.), Investors’ Rights Agreement (Elevation Oncology, Inc.)

Observer Rights. (a) As long as any Longitude Venture Partners IV, L.P. (together with its Affiliates, “Longitude”) owns shares of the Preferred Stock are outstanding (as adjusted for stock splits, stock combinations, stock dividends and the like)Stock, the Company shall invite a representative of Collage Venture Partners, LLC, a Florida limited liability company Longitude (the “Placement AgentLongitude Observer”), initially ▇▇▇▇▇▇ ▇▇▇▇▇▇▇, ) to attend all meetings of the its Board of Directors via telephone or video conference in a nonvoting observer capacity and, in this respect, shall give such representative the Longitude Observer copies of all notices, minutes, consents, and other materials that it provides to the Board of Directorsits directors; provided, however, that such representative Longitude Observer shall agree to hold in confidence and trust with respect to all information so provided; and provided further, that the Company reserves the right to withhold any information and to exclude such representative the Longitude Observer from any meeting or portion thereof if access to such information or attendance at such meeting would be reasonably likely to adversely affect the attorney-client privilege between the Company and its counsel, counsel or would result in disclosure of trade secrets or highly confidential information, create a competitive harm or competitive disadvantage, or relates to subject matter in which the Placement Agent may have a conflict of interest, or if the Placement Agent or its representative is a CompetitorLongitude Observer. (b) In the event that ▇.▇. ▇▇▇▇▇▇▇ As long as Red Tree Venture Fund, L.P. (together with its Affiliates, “▇▇. ▇▇▇▇▇▇▇Red Tree”) is not elected to the Board as the Series B Director (as defined in the Voting Agreement) and so long as Transhuman Capital, LLC, a Delaware limited liability company (“Transhuman”) and CRS Capital, LLC, a Michigan limited liability company (“CRS”), together with their Affiliates, own at least 1,000,000 owns shares of Series B the Preferred Stock purchased under the Purchase Agreement (as adjusted for stock splits, stock combinations, stock dividends and the like)Stock, the Company shall invite ▇▇. ▇▇▇▇▇▇▇ a representative of Red Tree (the “Red Tree Observer”) to attend all meetings of the its Board of Directors via telephone or video conference in a nonvoting observer capacity and, in this respect, shall give such representative the Red Tree Observer copies of all notices, minutes, consents, and other materials that it provides to the Board of Directorsits directors; provided, however, that such representative Red Tree Observer shall agree to hold in confidence and trust with respect to all information so provided; and provided further, that the Company reserves the right to withhold any information and to exclude such representative the Red Tree Observer from any meeting or portion thereof if access to such information or attendance at such meeting would be reasonably likely to adversely affect the attorney-client privilege between the Company and its counsel, counsel or would result in disclosure of trade secrets to the Red Tree Observer or if Red Tree or its representative is or is affiliated with a direct competitor of the Company. (c) As long as RA Capital Healthcare Fund, L.P. and/or RA Capital Nexus Fund II, L.P. (together with their Affiliates, “RA Capital”) owns shares of the Preferred Stock, the Company shall invite a representative of RA Capital (the “RA Capital Observer”) to attend all meetings of its Board of Directors via telephone or video conference in a nonvoting observer capacity and, in this respect, shall give the RA Capital Observer copies of all notices, minutes, consents, and other materials that it provides to its directors; provided, however, that RA Capital Observer shall agree to hold in confidence and trust with respect to all information so provided; and provided further, that the Company reserves the right to withhold any information and to exclude the RA Capital Observer from any meeting or portion thereof if access to such information or attendance at such meeting would adversely affect the attorney-client privilege between the Company and its counsel or would result in disclosure of trade secrets to the RA Capital Observer or if RA Capital or its representative is or is affiliated with a direct competitor of the Company. (d) For so long as LivaNova USA, Inc. (“LivaNova”) or any of its subsidiaries or Affiliates (each, including LivaNova, a “LivaNova Party” and collectively, the “LivaNova Parties”) holds any of the shares of Series B Preferred Stock (including any Common Stock into which such shares are convertible), the LivaNova Parties shall have the right to designate one representative (the “LivaNova Observer”) to attend and observe all meetings of the Board of Directors via telephone or video conference in a nonvoting observer capacity, and, in this respect, the Company shall provide the LivaNova Observer with copies of all notices, minutes, consents and other material (“Materials”) that it provides to the members of the Board of Directors, at the same time and in the same manner as the respective members of the Board of Director; provided, however, that the Company reserves the right to exclude the LivaNova Observer from access to any Material or meeting or portion thereof if the Board of Directors determines in good faith, upon the advice of counsel, that such exclusion is reasonably necessary to (i) preserve the attorney-client privilege, (ii) protect highly confidential proprietary information, create a competitive harm or competitive disadvantage, or relates to subject matter in which Transhuman or CRS may have (iii) avoid a conflict of interestinterest with ▇▇▇▇▇▇▇▇. ▇▇▇▇▇▇▇▇ agrees that the LivaNova Observer shall be selected by consulting with the Company’s CEO, and shall have no less than ten years of experience in the health care industry (or be a Vice President or comparable role) and be a fluent English speaker. Upon reasonable notice and at a scheduled meeting of the Board of Directors or such other time, if Transhumanany, CRS or their representative is a Competitoras the Board of Directors may determine in its sole discretion, the LivaNova Observer may address the Board of Directors with respect to LivaNova’s concerns regarding significant business issues facing the Company.

Appears in 2 contracts

Sources: Investors’ Rights Agreement (Ceribell, Inc.), Investors’ Rights Agreement (Ceribell, Inc.)

Observer Rights. (a) As long as any Sectoral owns at least 50% of the (i) shares of Series C-1 Preferred Stock are outstanding and Series C-2 Preferred Stock that it purchased pursuant to that certain Series C Stock Purchase Agreement, dated as of April 28, 2022 (including shares of Class A Common Stock issued upon conversion of Series C-1 Preferred Stock and Series C-2 Preferred Stock) and (ii) shares of Series C-3 Preferred Stock that it purchased pursuant to that certain Series C-3 Purchase Agreement, dated as adjusted for stock splitsof December 22, stock combinations, stock dividends and the like2022 (including shares of Class A Common Stock issued upon conversion of Series C-3 Preferred Stock), the Company shall invite a representative of Collage Venture Partners, LLC, a Florida limited liability company (the “Placement Agent”), initially ▇▇▇▇▇▇ ▇▇▇▇▇▇▇, Sectoral to attend all meetings of the Board of Directors in a nonvoting observer capacity and, in this respect, (the “Sectoral Board Observer”). The Company shall give such representative provide the Sectoral Board Observer with copies of all notices, minutes, consents, consents and other materials that it the Company provides its directors at any such meeting at the same time and in the same manner as provided to the Board of Directorssuch director; provided, however, that such representative the Sectoral Board Observer shall agree to hold in confidence all information so provided; provided further that Section 3.5 of this Agreement shall apply to any information so provided to the Sectoral Board Observer, mutatis mutandis; provided, further, the Company reserves the right to withhold any information and to exclude the Sectoral Board Observer from any meeting or portion thereof if: (i) the Company believes it is reasonably necessary to preserve attorney-client privilege between the Company and its counsel; (ii) access to such information or attendance at such meeting could result in disclosure of trade secrets; or (iii) access to such information or attendance at such meeting could result in a conflict of interest between the Sectoral Board Observer and/or Affiliates of the Sectoral Board Observer and the Company or its counsel. The Company shall in good faith endeavor to ensure that meetings of the Board or committees thereof are conducted in such a manner as to minimize those portions during which the Sectoral Board Observer shall be excluded, with a view of allowing the Sectoral Board Observer to attend and observe such meetings to the maximum extent possible. (b) As long as Columbia owns (i) at least 50% of the shares of Series B Preferred Stock that it purchased pursuant to that certain Series B Stock Purchase Agreement, dated as of March 12, 2021 (including shares of Class A Common Stock issued upon conversion of Series B Preferred Stock), (ii) at least 50% of the shares of Series D Preferred Stock that it purchased pursuant to that certain Series D Preferred Stock Purchase Agreement dated as of April 23, 2025 (including shares of Class A Common Stock issued upon conversion of Series D Preferred Stock), and (iii) at least 50% of the shares of Series D-1 Preferred Stock that it purchased pursuant to the Purchase Agreement, the Company shall invite a representative of each of Columbia to attend all meetings of the Board in a nonvoting observer capacity (the “Columbia Board Observer”). The Company shall provide the Columbia Board Observer with copies of all notices, minutes, consents and other materials that the Company provides its directors at any such meeting at the same time and in the same manner as provided to such director; provided, however, that the Columbia Board Observer shall agree to hold in confidence all information so provided; provided, further, the Company reserves the right to withhold any information and to exclude the Columbia Board Observer from any meeting or portion thereof if: (i) the Company believes it is reasonably necessary to preserve attorney-client privilege between the Company and its counsel; (ii) access to such information or attendance at such meeting could result in disclosure of trade secrets; (iii) access to such information or attendance at such meeting could result in a conflict of interest between the Columbia Board Observer and/or Affiliates of the Columbia Board Observer and the Company or its counsel; or (iv) the Columbia Board Observer represents and/or is affiliated with a competitor of the Company. The Company shall in good faith endeavor to ensure that meetings of the Board or committees thereof are conducted in such a manner as to minimize those portions during which the Columbia Board Observer shall be excluded, with a view of allowing the Columbia Board Observer to attend and observe such meetings to the maximum extent possible. (c) As long as Alpha Wave owns at least 50% of (i) the shares of Series C-1 Preferred Stock and Series C-2 Preferred Stock that it purchased pursuant to that certain Series C Stock Purchase Agreement, dated as of April 28, 2022 (including shares of Class A Common Stock issued upon conversion of Series C-1 Preferred Stock and Series C-2 Preferred Stock) and (ii) shares of Series C-3 Preferred Stock that it purchased pursuant to that certain Series C-3 Purchase Agreement, dated as of December 22, 2022 (including shares of Class A Common Stock issued upon conversion of Series C-3 Preferred Stock), the Company shall invite a representative of Alpha Wave to attend all meetings of the Board in a nonvoting observer capacity (the “Alpha Wave Board Observer”). The Company shall provide the Alpha Wave Board Observer with copies of all notices, minutes, consents and other materials that the Company provides its directors at any such meeting at the same time and in the same manner as provided to such director; provided, however, that the Alpha Wave Board Observer shall agree to hold in confidence all information so provided; provided further that Section 3.5 of this Agreement shall apply to any information so provided to the Alpha Wave Board Observer, mutatis mutandis; provided, further, the Company reserves the right to withhold any information and to exclude the Alpha Wave Board Observer from any meeting or portion thereof if: (i) the Company believes it is reasonably necessary to preserve attorney-client privilege between the Company and its counsel; (ii) access to such information or attendance at such meeting could result in disclosure of trade secrets; (iii) access to such information or attendance at such meeting could result in a conflict of interest between the Alpha Wave Board Observer and/or Affiliates of the Alpha Wave Board Observer and the Company or its counsel. The Company shall in good faith endeavor to ensure that meetings of the Board or committees thereof are conducted in such a manner as to minimize those portions during which the Alpha Wave Board Observer shall be excluded, with a view of allowing the Alpha Wave Board Observer to attend and observe such meetings to the maximum extent possible. (d) As long as Shionogi owns at least 50% of the shares of Class B Common Stock and Class C Common Stock that it purchased pursuant to Purchase Agreement and that certain Common Stock Purchase Agreement, dated as of November 1, 2023 (including shares of Class A Common Stock issued upon conversion of the Class B Common Stock and the Class C Common Stock), the Company shall invite a representative of Shionogi to attend all meetings of the Board in a nonvoting observer capacity (the “Shionogi Board Observer”). The Company shall provide the Shionogi Board Observer with copies of all notices, minutes, consents and other materials that the Company provides its directors at any such meeting at the same time and in the same manner as provided to such director; provided, however, that the Shionogi Board Observer shall agree to hold in confidence all information so provided in accordance with Section 3.5; provided further that Section 3.5 of this Agreement shall apply to any information so provided to the Shionogi Board Observer, mutatis mutandis; provided, further, that the Company reserves the right to withhold any information and to exclude such representative the Shionogi Board Observer from any meeting or portion thereof if access if: (i) the Company believes it is reasonably necessary to such information or attendance at such meeting would be reasonably likely to adversely affect the preserve attorney-client privilege between the Company and its counsel, result in disclosure of trade secrets or highly confidential information, create a competitive harm or competitive disadvantage, or relates to subject matter in which the Placement Agent may have a conflict of interest, or if the Placement Agent or its representative is a Competitor. ; (bii) In the event that ▇.▇. ▇▇▇▇▇▇▇ (“▇▇. ▇▇▇▇▇▇▇”) is not elected to the Board as the Series B Director (as defined in the Voting Agreement) and so long as Transhuman Capital, LLC, a Delaware limited liability company (“Transhuman”) and CRS Capital, LLC, a Michigan limited liability company (“CRS”), together with their Affiliates, own at least 1,000,000 shares of Series B Preferred Stock purchased under the Purchase Agreement (as adjusted for stock splits, stock combinations, stock dividends and the like), the Company shall invite ▇▇. ▇▇▇▇▇▇▇ to attend all meetings of the Board of Directors in a nonvoting observer capacity and, in this respect, shall give such representative copies of all notices, minutes, consents, and other materials that it provides to the Board of Directors; provided, however, that such representative shall agree to hold in confidence all information so provided; and provided further, that the Company reserves the right to withhold any information and to exclude such representative from any meeting or portion thereof if access to such information or attendance at such meeting would be reasonably likely to adversely affect the attorney-client privilege between the Company and its counsel, could result in disclosure of trade secrets not already disclosed to Shionogi; or highly confidential information, create a competitive harm (iii) access to such information or competitive disadvantage, or relates to subject matter attendance at such meeting could result in which Transhuman or CRS may have a conflict of interestinterest between the Shionogi Board Observer and/or Affiliates of the Shionogi Board Observer and the Company or its counsel. The Company shall in good faith endeavor to ensure that meetings of the Board or committees thereof are conducted in such a manner as to minimize those portions during which the Shionogi Board Observer shall be excluded, or if Transhuman, CRS or their representative is with a Competitorview of allowing the Shionogi Board Observer to attend and observe such meetings to the maximum extent possible.

Appears in 2 contracts

Sources: Investors’ Rights Agreement (Apnimed, Inc.), Investors’ Rights Agreement (Apnimed, Inc.)

Observer Rights. (a) As long as If at any shares time (i) CGI Opportunity Fund II, L.P. (“Contrarian”) has not elected a designee to the Board of Preferred Stock are outstanding Directors and (as adjusted for stock splitsii) Contrarian is the owner of at least 970,000 Shares, stock combinations, stock dividends and the like), the Company Contrarian shall invite a be entitled to appoint one representative of Collage Venture Partners, LLC, a Florida limited liability company (the “Placement Agent”), initially ▇▇▇▇▇▇ ▇▇▇▇▇▇▇, to attend all meetings each meeting (including telephonic meetings) of the Board of Directors in a nonvoting observer capacity and, (the “Contrarian Board Observer”). The Contrarian Board Observer shall be entitled to receive notice of each such meeting in this respect, shall give such representative copies the same form and manner as is given to the members of all notices, minutes, consents, and other materials that it provides to the Board of Directors (the “Directors; provided”) and the same materials as and when provided to the Directors. The Board of Directors shall not conduct any material business by written consent without giving notice (which may be after the fact) to the Contrarian Board Observer. The foregoing notwithstanding, however, that such representative shall agree to hold in confidence all information so provided; and provided further, that the Company reserves the right to withhold any information and to exclude such representative Contrarian Board Observer may be excluded from any meeting or portion thereof if access receiving any information to such information the extent necessary or attendance at such meeting would be reasonably likely appropriate to adversely affect protect any confidential matters discussed therein, as necessary or appropriate to protect the Company’s attorney-/client privilege between or in the Company and its counsel, result event that the Board of Directors reasonably determines in disclosure of trade secrets or highly confidential information, create good faith that the Contrarian Board Observer has a competitive harm or competitive disadvantage, or relates to subject matter in which the Placement Agent may have a conflict of conflicting interest, or if the Placement Agent or its representative is a Competitor. (b) In the event that ▇.▇. ▇▇▇▇▇▇▇ If at any time (i) CVV Partners L.P. (“▇▇. ▇▇▇▇▇▇▇CVVP”) is has not elected a designee to the Board as of Directors and (ii) CVVP is the Series B Director (as defined in the Voting Agreement) and so long as Transhuman Capital, LLC, a Delaware limited liability company (“Transhuman”) and CRS Capital, LLC, a Michigan limited liability company (“CRS”), together with their Affiliates, own owner of at least 1,000,000 shares of Series B Preferred Stock purchased under the Purchase Agreement (as adjusted for stock splits120,000 Shares, stock combinations, stock dividends and the like), the Company CVVP shall invite ▇▇. ▇▇▇▇▇▇▇ be entitled to appoint one representative to attend all meetings each meeting (including telephonic meetings) of the Board of Directors in a nonvoting observer capacity and(the “CVVP Board Observer”). The CVVP Board Observer shall be entitled to receive notice of each such meeting in the same form and manner as is given to the Directors and the same materials as and when provided to the Directors. The Board of Directors shall not conduct any material business by written consent without giving notice (which may be after the fact) to the CVVP Board Observer. The foregoing notwithstanding, the CVVP Board Observer may be excluded from any meeting or receiving any information to the extent necessary or appropriate to protect any confidential matters discussed therein, as necessary or appropriate to protect the Company’s attorney/client privilege or in this respectthe event that the Board of Directors reasonably determines in good faith that the CVVP Board Observer has a conflicting interest. (c) If at any time (i) One Earth Capital, shall give such representative copies of all notices, minutes, consents, and other materials that it provides LLC (“One Earth”) has not elected a designee to the Board of Directors and (ii) One Earth is the owner of at least 970,000 Shares, One Earth shall be entitled to appoint one representative to attend each meeting (including telephonic meetings) of the Board of Directors in a nonvoting observer capacity (the “One Earth Board Observer”). The One Earth Board Observer shall be entitled to receive notice of each such meeting in the same form and manner as is given to the Directors and the same materials as and when provided to the Directors; provided. The Board of Directors shall not conduct any material business by written consent without giving notice (which may be after the fact) to the One Earth Board Observer. The foregoing notwithstanding, however, that such representative shall agree to hold in confidence all information so provided; and provided further, that the Company reserves the right to withhold any information and to exclude such representative One Earth Board Observer may be excluded from any meeting or portion thereof if access receiving any information to such information the extent necessary or attendance at such meeting would be reasonably likely appropriate to adversely affect protect any confidential matters discussed therein, as necessary or appropriate to protect the Company’s attorney-/client privilege between or in the Company event that the Board of Directors reasonably determines in good faith that the One Earth Board Observer has a conflicting interest. (d) If at any time (i) Stuart Mill Venture Partners, L.P. (“SMVP”) has not elected a designee to the Board of Directors and its counsel(ii) SMVP is the owner of at least 970,000 Shares, result SMVP shall be entitled to appoint one representative to attend each meeting (including telephonic meetings) of the Board of Directors in disclosure of trade secrets or highly confidential information, create a competitive harm or competitive disadvantage, or relates to subject matter in which Transhuman or CRS may have a conflict of interest, or if Transhuman, CRS or their representative is a Competitor.nonvoting observer capacity (the “SMVP

Appears in 2 contracts

Sources: Investor Rights Agreement (Marrone Bio Innovations Inc), Investor Rights Agreement (Marrone Bio Innovations Inc)

Observer Rights. (a) As long at least fifty percent (50%) of the Series A-1 Preferred Units as of the Effective Date remain outstanding Series A-1 Preferred Units (for such purpose, any shares Series A-1 Preferred Units held by an Affiliate of Preferred Stock are outstanding a Series A-1 Member shall be treated as owned by such Series A-1 Member) (as adjusted for stock splits, stock combinations, stock dividends and the likeor an equivalent amount of Common Units issued upon conversion thereof), the Company LLC shall invite a one representative of Collage Venture Partners, LLC, a Florida limited liability company the Members holding Series A-1 Preferred Units (the “Placement AgentSeries A-1 Representative”), initially ▇▇▇▇▇▇ ▇▇▇▇▇▇▇, ) to attend all meetings of the its Board of Directors Managers in a nonvoting observer capacity and, in this respect, shall give such representative copies of all notices, minutes, consents, consents and other materials that it provides to its Managers at the Board of Directorssame time the LLC provides such information to its Managers; provided, however, that such representative Series A-1 Representative shall agree to hold in confidence and trust and to act in a fiduciary manner with respect to all information so provided; and and, provided further, that the Company LLC reserves the right to withhold any information and to exclude such representative Series A-1 Representative from any meeting or portion thereof if access to such information or attendance at such meeting would be reasonably likely to (a) could adversely affect the attorney-client attorney‑client privilege between the Company LLC and its counsel, (b) would result in disclosure of trade secrets or highly confidential information, create a competitive harm or competitive disadvantageto such Series A-1 Representative, or relates to subject matter in which the Placement Agent may have a conflict (c) if PDV or any of interest, or if the Placement Agent or its representative Affiliates is a Competitor. Competitor of the LLC (b) In provided that an Affiliate of PDV shall not be deemed to be a Competitor of the event that ▇.▇. ▇▇▇▇▇▇▇ (“▇▇. ▇▇▇▇▇▇▇”) LLC if such Affiliate is not elected to the Board as the Series B Director (as defined in the Voting Agreement) and so long as Transhuman Capital, LLC, a Delaware limited liability company (“Transhuman”) and CRS Capital, LLC, a Michigan limited liability company (“CRS”)financial investment entity that, together with their Affiliatesits Affiliated funds or entities, own at least 1,000,000 shares holds outstanding equity of any Competitor), or (d) would result in a business conflict of interest in regards to PDV and the LLC, other than as a result of PDV’s ownership of Series B A-1 Preferred Stock purchased under the Purchase Agreement Units (as adjusted for stock splitsreasonably determined by the Board of Managers in good faith). In addition, stock combinations, stock dividends the Series A-1 Members (or any authorized representative designated by the Series A-1 Members) shall have the right to consult with and advise the Board of Managers and the likemanagement of the LLC, upon reasonable notice at reasonable times from time to time, on all matters relating to the operation of the LCC. The LLC agrees to consider, in good faith, the recommendations of Series A-1 Members (or its authorized representative) in connection with the matters on which it is consulted as described above, recognizing that the ultimate discretion with respect to all such matters shall be retained by the LLC. Notwithstanding the foregoing, if PDV sells or otherwise transfers its Series A-1 Preferred Units to a Competitor of the LLC (including as a result of the competitor acquiring PDV or substantially all of the PDV’s assets), the Company shall invite ▇▇. ▇▇▇▇▇▇▇ right of the Series A-1 Members to attend all meetings of appoint a Series A-1 Representative and its rights to consult with the Board of Directors Managers and management of the LLC shall terminate. Any observer shall be required to enter into a confidentiality agreement containing substantially similar terms as those set forth in a nonvoting observer capacity and, Section 8.8 of this Agreement with the LLC prior to the exercise of the rights contained in this respect, shall give such representative copies of all notices, minutes, consents, and other materials that it provides to the Board of Directors; provided, however, that such representative shall agree to hold in confidence all information so provided; and provided further, that the Company reserves the right to withhold any information and to exclude such representative from any meeting or portion thereof if access to such information or attendance at such meeting would be reasonably likely to adversely affect the attorney-client privilege between the Company and its counsel, result in disclosure of trade secrets or highly confidential information, create a competitive harm or competitive disadvantage, or relates to subject matter in which Transhuman or CRS may have a conflict of interest, or if Transhuman, CRS or their representative is a CompetitorSection 5.4.

Appears in 1 contract

Sources: Limited Liability Company Agreement (pdvWireless, Inc.)

Observer Rights. (a) As long as (i) Atlas Venture holds any shares of Preferred Stock are outstanding (as adjusted for stock splits, stock combinations, stock dividends and the like)or Common Stock, the Company shall invite a representative of Collage Atlas Venture Partners, LLC, a Florida limited liability company (the “Placement Agent”), initially ▇▇▇▇▇▇ ▇▇▇▇▇▇▇, to attend all meetings of its Board of Directors and all meetings of committees of the Board of Directors in a nonvoting observer capacity, (ii) Third Rock Ventures, LP (“Third Rock”) holds any shares of Preferred Stock or Common Stock, the Company shall invite a representative of Third Rock to attend all meetings of its Board of Directors and all meetings of committees of the Board of Directors in a nonvoting observer capacity, (iii) Alta Partners VIII, LP (“Alta Partners”) or any Affiliate of Alta Partners holds any shares of Preferred Stock or Common Stock, the Company shall invite a representative of Alta Partners to attend all meetings of its Board of Directors and all meetings of committees of the Board of Directors in a nonvoting observer capacity and (iv) RA Capital Management, LLC (“RA Capital”) or any Affiliate of RA Capital holds any shares of Preferred Stock or Common Stock, the Company shall invite a representative of RA Capital to attend all meetings of its Board of Directors in a nonvoting observer capacity, and, in this respect, shall give any such representative copies of all notices, minutes, consents, and other materials that it provides to its directors at the Board of Directorssame time and in the same manner as provided to such directors; provided, however, that any such representative shall agree to hold in confidence and trust and to act in a fiduciary manner with respect to all information so provided; and provided further, that the Company reserves the right to withhold any information and to exclude any such representative from any meeting or portion thereof if access to such information or attendance at such meeting would be reasonably likely to could adversely affect the attorney-client privilege between the Company and its counsel, counsel or result in disclosure of trade secrets or highly confidential information, create a competitive harm or competitive disadvantage, or relates to subject matter in which the Placement Agent may have a conflict of interest, or if the Placement Agent such Investor or its representative is a Competitor. (b) In competitor of the event that ▇.▇Company. ▇▇▇▇▇▇▇ (“▇▇. ▇▇▇▇▇▇▇”) is not elected to To the Board as the Series B Director (as defined in the Voting Agreement) and so long as Transhuman Capital, LLC, a Delaware limited liability company (“Transhuman”) and CRS Capital, LLC, a Michigan limited liability company (“CRS”), together with their Affiliates, own at least 1,000,000 shares of Series B Preferred Stock purchased under the Purchase Agreement (as adjusted for stock splits, stock combinations, stock dividends and the like), extent the Company provides indemnification to any Board of Directors observer, it shall invite ▇▇provide the same indemnification to all such observers. ▇▇▇▇▇▇▇ The Company will reimburse the representative of Alta Partners pursuant to this section for the reasonable expenses incurred by such representative for travel to attend all meetings of the Board of Directors in a nonvoting observer capacity and, in this respect, shall give such representative copies or any committee of all notices, minutes, consents, and other materials that it provides to the Board of Directors; provided, however, that such representative shall agree to hold in confidence all information so provided; and provided further, that the Company reserves the right to withhold any information and to exclude such representative from any meeting or portion thereof if access to such information or attendance at such meeting would be reasonably likely to adversely affect the attorney-client privilege between the Company and its counsel, result in disclosure of trade secrets or highly confidential information, create a competitive harm or competitive disadvantage, or relates to subject matter in which Transhuman or CRS may have a conflict of interest, or if Transhuman, CRS or their representative is a Competitor.

Appears in 1 contract

Sources: Investors’ Rights Agreement (Zafgen, Inc.)

Observer Rights. (a) As long as any Abingworth owns not less than twenty-five percent (25%) of the shares of the Series C Preferred Stock are outstanding it is purchasing under the Purchase Agreement (as adjusted for stock splits, stock combinations, stock dividends and the likeor an equivalent amount of Common Stock issued upon conversion thereof), the Company shall invite a representative of Collage Venture Partners, LLC, a Florida limited liability company (the “Placement Agent”), initially ▇▇▇▇▇▇ ▇▇▇▇▇▇▇, Abingworth to attend all meetings of the Board of Directors in a nonvoting observer capacity and, in this respect, shall give such representative copies of all notices, minutes, consents, and other materials that it provides to its directors at the Board of Directorssame time and in the same manner as provided to such directors; provided, however, that such representative shall agree to hold in confidence all information so provided; and provided further, that the Company reserves the right to withhold any information and to exclude such representative from any meeting or portion thereof if access to such information or attendance at such meeting would be reasonably likely to could adversely affect the attorney-client privilege between the Company and its counsel, result in disclosure of trade secrets or highly confidential information, create a competitive harm or competitive disadvantage, or relates to subject matter in which the Placement Agent may have a conflict of interest, or if the Placement Agent or its representative is a Competitor. (b) In As long as Longitude owns not less than twenty-five percent (25%) of the event that ▇.▇. ▇▇▇▇▇▇▇ (“▇▇. ▇▇▇▇▇▇▇”) is not elected to the Board as shares of the Series B Director (as defined in the Voting Agreement) and so long as Transhuman Capital, LLC, a Delaware limited liability company (“Transhuman”) and CRS Capital, LLC, a Michigan limited liability company (“CRS”), together with their Affiliates, own at least 1,000,000 shares of Series B C Preferred Stock purchased it is purchasing under the Purchase Agreement (as adjusted for stock splits, stock combinations, stock dividends and the likeor an equivalent amount of Common Stock issued upon conversion thereof), the Company shall invite ▇▇. ▇▇▇▇▇▇▇ a representative of Longitude to attend all meetings of the Board of Directors in a nonvoting observer capacity and, in this respect, shall give such representative copies of all notices, minutes, consents, and other materials that it provides to its directors at the Board of Directorssame time and in the same manner as provided to such directors; provided, however, that such representative shall agree to hold in confidence all information so provided; and provided further, that the Company reserves the right to withhold any information and to exclude such representative from any meeting or portion thereof if access to such information or attendance at such meeting would be reasonably likely to could adversely affect the attorney-client privilege between the Company and its counsel. (c) As long as Sofinnova owns not less than twenty-five percent (25%) of the shares of the Series C Preferred Stock it is purchasing under the Purchase Agreement (or an equivalent amount of Common Stock issued upon conversion thereof), result the Company shall invite a representative of Sofinnova to attend all meetings of the Board of Directors in disclosure a nonvoting observer capacity and, in this respect, shall give such representative copies of trade secrets all notices, minutes, consents, and other materials that it provides to its directors at the same time and in the same manner as provided to such directors; provided, however, that such representative shall agree to hold in confidence all information so provided; and provided further, that the Company reserves the right to withhold any information and to exclude such representative from any meeting or highly confidential informationportion thereof if access to such information or attendance at such meeting could adversely affect the attorney-client privilege between the Company and its counsel. (d) As long as Surveyor owns not less than twenty-five percent (25%) of the shares of the Series C Preferred Stock it is purchasing under the Purchase Agreement (or an equivalent amount of Common Stock issued upon conversion thereof), create the Company shall invite a competitive harm representative of Surveyor to attend all meetings of the Board of Directors in a nonvoting observer capacity and, in this respect, shall give such representative copies of all notices, minutes, consents, and other materials that it provides to its directors at the same time and in the same manner as provided to such directors; provided, however, that such representative shall agree to hold in confidence all information so provided; and provided further, that the Company reserves the right to withhold any information and to exclude such representative from any meeting or competitive disadvantageportion thereof if access to such information or attendance at such meeting could adversely affect the attorney-client privilege between the Company and its counsel. (e) As long as Ares Trading S.A. (“ATSA”) owns not less than twenty-five percent (25%) of the shares of the Series C Preferred Stock issued to it under the Purchase Agreement (or an equivalent amount of Common Stock issued upon conversion thereof), the Company shall invite a representative of ATSA to attend all meetings of the Board of Directors in a nonvoting observer capacity and, in this respect, shall give such representative copies of all notices, minutes, consents, and other materials that it provides to its directors at the same time and in the same manner as provided to such directors; provided, however, that such representative shall agree to hold in confidence all information so provided; and provided further, that the Company reserves the right to withhold any information and to exclude such representative from any meeting or relates portion thereof if access to subject matter in which Transhuman such information or CRS may have a conflict of interest, or if Transhuman, CRS or their representative is a Competitorattendance at such meeting could adversely affect the attorney-client privilege between the Company and its counsel.

Appears in 1 contract

Sources: Investors’ Rights Agreement (Vera Therapeutics, Inc.)

Observer Rights. Tinicum may designate one Person, in the aggregate, to attend meetings of the Board of Directors and the Compensation Committee as an observer (a) As “Observer”), for so long as any shares Tinicum beneficially owns 10% or more of Preferred Stock are the then outstanding (as adjusted for stock splits, stock combinations, stock dividends and Common Stock. If Tinicum beneficially owns less than 10% of the like)then outstanding Common Stock, the Company shall invite a representative of Collage Venture Partners, LLC, a Florida limited liability company (the “Placement Agent”), initially ▇▇▇▇▇▇ ▇▇▇▇▇▇▇, have no obligation pursuant to this Agreement to permit any Person designated by Tinicum to attend meetings of the Board of Directors, the Compensation Committee or otherwise under this Section 4.4. The Observer shall be entitled to receive notice of and have the right to attend any and all meetings of the Board of Directors and the Compensation Committee in a nonvoting an observer capacity andcapacity, in this respect, and the Company shall give such representative provide the Observer with copies of all notices, minutes, consents, consents and other material in connection therewith at the same time as such materials that it provides are distributed to members of the Board of DirectorsDirectors and the Compensation Committee; provided, however, that such representative (A) Tinicum shall cause the Observer to agree to hold in confidence and trust and to act in a fiduciary manner with respect to all information so provided; provided to such Observer pursuant hereto and provided further(B) the Company, that the Company reserves Board of Directors and the Compensation Committee shall have the right to withhold any information and to exclude such representative Observer from any meeting or portion thereof (1) if access doing so is, in the opinion of counsel to such information the Company, advisable or attendance at such meeting would be reasonably likely necessary to adversely affect protect the attorney-client privilege between the Company and its counsel or (2) if the Board of Directors or the Compensation Committee determines in good faith, after consultation with counsel, result in disclosure of trade secrets or highly confidential information, create a competitive harm or competitive disadvantage, or relates that fiduciary requirements under applicable law would make attendance by such Observer not advisable. The Observers shall have no right to subject matter in which the Placement Agent may have a conflict of interest, or if the Placement Agent or its representative is a Competitor. (b) In the event that ▇.▇. ▇▇▇▇▇▇▇ (“▇▇. ▇▇▇▇▇▇▇”) is not elected vote on any matters presented to the Board as of Directors or the Series B Director (as defined in Compensation Committee. All obligations of the Voting Agreement) and so long as Transhuman CapitalCompany pursuant to this Section 4.4 shall terminate, LLCand, a Delaware limited liability company (“Transhuman”) and CRS Capitalupon request by the Board of Directors, LLC, a Michigan limited liability company (“CRS”), together with their Affiliates, own at least 1,000,000 shares Tinicum shall cause the Observer to resign promptly from the Board of Series B Preferred Stock purchased under the Purchase Agreement (as adjusted for stock splits, stock combinations, stock dividends Directors and the like)Compensation Committee, in each case upon Tinicum ceasing to have the Company right to designate an Observer pursuant to this Section 4.4. In addition, upon request by the Board of Directors, Tinicum shall invite ▇▇cause its Observer to resign promptly at any time that Tinicum is no longer entitled to nominate or designate an Observer pursuant to this Section 4.4. ▇▇▇▇▇▇▇ The Observer shall be entitled to attend all reimbursement for documented, reasonable out-of-pocket expenses incurred in attending meetings of the Board of Directors in a nonvoting observer capacity andand the Compensation Committee, in this respect, shall give such representative copies to the same extent as members of all notices, minutes, consents, and other materials that it provides to the Board of Directors; provided, however, that such representative shall agree to hold in confidence all information so provided; Directors and provided further, that the Company reserves the right to withhold any information and to exclude such representative from any meeting or portion thereof if access to such information or attendance at such meeting would be reasonably likely to adversely affect the attorney-client privilege between the Company and its counsel, result in disclosure of trade secrets or highly confidential information, create a competitive harm or competitive disadvantage, or relates to subject matter in which Transhuman or CRS may have a conflict of interest, or if Transhuman, CRS or their representative is a CompetitorCompensation Committee.

Appears in 1 contract

Sources: Investment Agreement (X Rite Inc)

Observer Rights. (a) As long as any Sofinnova Investments owns not less 5,000,000 shares of the Preferred Stock are outstanding (as adjusted for stock splits, stock combinations, stock dividends and the likeor an equivalent amount of Common Stock issued upon conversion thereof), the Company shall invite a representative of Collage Venture Partners, LLC, a Florida limited liability company (the “Placement Agent”), initially ▇▇▇▇▇▇ ▇▇▇▇▇▇▇, Sofinnova Investments to attend all meetings of the Board of Directors in a nonvoting observer capacity and, in this respect, shall give such representative copies of all notices, minutes, consents, and other materials that it provides to its directors at the Board of Directorssame time and in the same manner as provided to such directors; provided, however, that such representative shall agree to hold in confidence and trust and to act in a fiduciary manner with respect to all information so provided; and provided further, that the Company reserves the right to withhold any information and to exclude such representative from any meeting or portion thereof if access to such information or attendance at such meeting would be reasonably likely to could adversely affect the attorney-client privilege between the Company and its counsel, counsel or result in disclosure of trade secrets or highly confidential information, create a competitive harm or competitive disadvantage, or relates to subject matter in which the Placement Agent may have a conflict of interest, or if the Placement Agent such Investor or its representative is a CompetitorCompetitor of the Company. (b) In the event that ▇.▇. ▇▇▇▇▇▇▇ (“▇▇. ▇▇▇▇▇▇▇”) is not elected to the Board as the Series B Director (as defined in the Voting Agreement) and so As long as Transhuman Capital, LLC, a Delaware limited liability company (“Transhuman”) and CRS Capital, LLC, a Michigan limited liability company (“CRS”), together with their Affiliates, own at least 1,000,000 5AM owns not less than 5,000,000 shares of Series B the Preferred Stock purchased under the Purchase Agreement (as adjusted for stock splits, stock combinations, stock dividends and the likeor an equivalent amount of Common Stock issued upon conversion thereof), the Company shall invite ▇▇. ▇▇▇▇▇▇▇ a representative of 5AM to attend all meetings of the Board of Directors in a nonvoting observer capacity and, in this respect, shall give such representative copies of all notices, minutes, consents, and other materials that it provides to its directors at the Board of Directorssame time and in the same manner as provided to such directors; provided, however, that such representative shall agree to hold in confidence and trust and to act in a fiduciary manner with respect to all information so provided; and provided further, that the Company reserves the right to withhold any information and to exclude such representative from any meeting or portion thereof if access to such information or attendance at such meeting would be reasonably likely to could adversely affect the attorney-client privilege between the Company and its counsel, counsel or result in disclosure of trade secrets or highly confidential information, create a competitive harm or competitive disadvantage, or relates to subject matter in which Transhuman or CRS may have a conflict of interest, or if Transhuman, CRS such Investor or their its representative is a CompetitorCompetitor of the Company. (c) As long as General Atlantic owns not less than 4,125,000 shares of the Preferred Stock (or an equivalent amount of Common Stock issued upon conversion thereof), the Company shall invite a representative of General Atlantic to attend all meetings of the Board of Directors in a nonvoting observer capacity and, in this respect, shall give such representative copies of all notices, minutes, consents, and other materials that it provides to its directors at the same time and in the same manner as provided to such directors; provided, however, that such representative shall agree to hold in confidence and trust and to act in a fiduciary manner with respect to all information so provided; and provided further, that the Company reserves the right to withhold any information and to exclude such representative from any meeting or portion thereof if access to such information or attendance at such meeting could adversely affect the attorney-client privilege between the Company and its counsel or result in disclosure of trade secrets or a conflict of interest, or if such Investor or its representative is a Competitor of the Company. (d) As long as Omega owns not less than 750,000 shares of the Preferred Stock (or an equivalent amount of Common Stock issued upon conversion thereof), the Company shall invite a representative of Omega to attend all meetings of the Board of Directors in a nonvoting observer capacity and, in this respect, shall give such representative copies of all notices, minutes, consents, and other materials that it provides to its directors at the same time and in the same manner as provided to such directors; provided, however, that such representative shall agree to hold in confidence and trust and to act in a fiduciary manner with respect to all information so provided; and provided further, that the Company reserves the right to withhold any information and to exclude such representative from any meeting or portion thereof if access to such information or attendance at such meeting could adversely affect the attorney-client privilege between the Company and its counsel or result in disclosure of trade secrets or a conflict of interest, or if such Investor or its representative is a Competitor of the Company. (e) As long as venBio Global Strategic Fund III, L.P. together with its Affiliates (“venBio”) owns not less than 875,000 shares of the Preferred Stock (or an equivalent amount of Common Stock issued upon conversion thereof), the Company shall invite a representative of venBio to attend all meetings of the Board of Directors in a nonvoting observer capacity and, in this respect, shall give such representative copies of all notices, minutes, consents, and other materials that it provides to its directors at the same time and in the same manner as provided to such directors; provided, however, that such representative shall agree to hold in confidence and trust and to act in a fiduciary manner with respect to all information so provided; and provided further, that the Company reserves the right to withhold any information and to exclude such representative from any meeting or portion thereof if access to such information or attendance at such meeting could adversely affect the attorney-client privilege between the Company and its counsel or result in disclosure of trade secrets or a conflict of interest, or if such Investor or its representative is a Competitor of the Company.

Appears in 1 contract

Sources: Investors’ Rights Agreement (CinCor Pharma, Inc.)

Observer Rights. (a) As long as any shares of Preferred Stock are outstanding For the one year period following the Closing Date (as adjusted for stock splits, stock combinations, stock dividends and the like), the Company "Observer Period") NaviSite shall invite permit a representative (who shall be reasonably satisfactory to NaviSite) of Collage Venture Partners, LLC, a Florida limited liability company Convergence Partners (the “Placement Agent”), initially ▇▇▇▇▇▇ ▇▇▇▇▇▇▇, "Observer") to attend all meetings of the NaviSite's Board of Directors (the "Board"), and all committees thereof, in a nonvoting observer capacity andnon-voting capacity. During the Observer Period, in this respect, NaviSite shall give such representative provide the Observer with copies of all notices, minutes, consents, information and other materials of meetings of the Board and all committees thereof and all written consents, waivers and similar materials of the Board and all committees thereof that it NaviSite provides to its directors (collectively, the Board of Directors; provided"Materials"), however, that when and as such representative shall agree Materials are delivered to hold in confidence all information so provided; and provided further, that the Company reserves the right to withhold any information and to exclude such representative from any meeting or portion thereof if access to such information or attendance at such meeting would be reasonably likely to adversely affect the attorney-client privilege between the Company and its counsel, result in disclosure of trade secrets or highly confidential information, create a competitive harm or competitive disadvantage, or relates to subject matter in which the Placement Agent may have a conflict of interest, or if the Placement Agent or its representative is a CompetitorBoard. (b) In After the event that ▇.▇. ▇▇▇▇▇▇▇ (“▇▇. ▇▇▇▇▇▇▇”) is not elected to expiration of the Board as the Series B Director (as defined Observer Period, at such time, and only for so long as, Convergence Partners or entities affiliated therewith hold, in the Voting Agreement) aggregate, more than 4% of the outstanding shares of NaviSite capital stock, fully-diluted and so long on an as Transhuman Capitalconverted to Common Stock and basis (which shall include all outstanding options, LLC, a Delaware limited liability company (“Transhuman”) warrants and CRS Capital, LLC, a Michigan limited liability company (“CRS”other equity securities to acquire NaviSite capital stock and all outstanding debt securities convertible into shares of NaviSite capital stock), together with their Affiliates, own at least 1,000,000 shares of Series B Preferred Stock purchased under NaviSite shall permit the Purchase Agreement Observer (as adjusted for stock splits, stock combinations, stock dividends and the like), the Company who shall invite ▇▇. ▇▇▇▇▇▇▇ be reasonably satisfactory to NaviSite) to attend all meetings of the to Board of Directors and committee meetings, in a nonvoting observer non-voting capacity and, in this respect, and shall give such representative provide the Observer with copies of all noticesMaterials, minutes, consents, when and other materials that it provides as such Materials are delivered to the Board Board. (c) Notwithstanding the foregoing rights, NaviSite shall have the right, in its reasonable discretion based upon the potential for conflicts of Directors; providedinterest with Convergence that may arise, however, that such representative shall agree to hold in confidence all information so provided; and provided further, that the Company reserves the right to withhold any information and to exclude such representative from any meeting or portion thereof if access to such information or attendance at such meeting would be reasonably likely to adversely affect the matters of attorney-client privilege between or other reasonable purposes, to withhold all or a portion of any Materials from the Company and its counselObserver and/or exclude the Observer from all or any portion of a Board or committee meeting. (d) Failure to deliver any such Materials as noted above shall not invalidate any action of the Board or Committee of the Board taken at a meeting or by written consent. As a condition to attending meeting of the Board or committees thereof, result in disclosure of trade secrets or highly confidential information, create the Observer shall enter into a competitive harm or competitive disadvantage, or relates to subject matter in which Transhuman or CRS may have a conflict of interest, or if Transhuman, CRS or their representative is a Competitormutually acceptable confidentiality agreement with NaviSite.

Appears in 1 contract

Sources: Agreement and Plan of Merger and Reorganization (Navisite Inc)

Observer Rights. (a) As long as At any shares of Preferred Stock are outstanding (as adjusted for stock splits, stock combinations, stock dividends and the like), the Company shall invite a representative of Collage Venture Partners, LLC, a Florida limited liability company (the “Placement Agent”), initially time that ▇▇▇▇▇▇▇ does not have a representative on the Board, the Company shall allow one representative of ▇▇▇▇▇▇▇, for so long as ▇▇▇▇▇▇▇ and its Affiliates own not less than 20% of the shares of the Series B Preferred Stock owned by ▇▇▇▇▇▇▇ as of the date of this Agreement, to attend all meetings of the Board of Directors in a nonvoting observer capacity and, in this respect, (the “Puccini Observer”). The Company shall give such representative the Puccini Observer copies of all notices, minutes, consents, and other materials that it provides to its directors at the Board of Directors; provided, however, that such representative same time and in the same manner as provided to the Board. The Puccini Observer shall agree to hold in confidence and trust and to act in a fiduciary manner with respect to all information so provided; and provided further, that the . The Company reserves the right to withhold any information and to exclude such representative the Puccini Observer from any meeting or portion thereof if the Board reasonably believes that access to such information or attendance at such meeting would be reasonably likely to could adversely affect the attorney-client privilege between the Company and its counsel; provided that such Puccini Observer is an officer or a director of an entity that is reasonably determined by the Board to be a competitor of the Company, result in disclosure of trade secrets such Puccini Observer may be excluded from information or highly confidential information, create a competitive harm attendance at such meeting if the Board reasonably determines that such information or competitive disadvantage, or relates to subject matter in which the Placement Agent may have attendance would be a conflict of interest, or if the Placement Agent or its representative is a Competitor. (b) In the event that ▇.▇. interest between such ▇▇▇▇▇▇▇ Observer and the Company. (b) At any time that funds affiliated with RA Capital Management, L.P. (“▇▇. ▇▇▇▇▇▇▇RA Capital”) is does not elected to have a representative on the Board as Board, the Series B Director (as defined in the Voting Agreement) and Company shall allow one representative of RA Capital, for so long as Transhuman Capital, LLC, a Delaware limited liability company (“Transhuman”) and CRS Capital, LLC, a Michigan limited liability company (“CRS”), together with their Affiliates, own at least 1,000,000 RA Capital owns not less than 600,000 shares of Series B D Preferred Stock purchased under the Purchase Agreement (as adjusted subject to adjustment for stock splits, stock dividends, combinations, stock dividends and reclassifications or the like), the Company shall invite ▇▇. ▇▇▇▇▇▇▇ to attend all meetings of the Board of Directors in a nonvoting observer capacity and, in this respect, (the “RA Capital Observer”). The Company shall give such representative the RA Capital Observer copies of all notices, minutes, consents, and other materials that it provides to its directors at the Board of Directors; provided, however, that such representative same time and in the same manner as provided to the Board. The RA Capital Observer shall agree to hold in confidence and trust and to act in a fiduciary manner with respect to all information so provided; and provided further, that the . The Company reserves the right to withhold any information and to exclude such representative the RA Capital Observer from any meeting or portion thereof if the Board reasonably believes that access to such information or attendance at such meeting would be reasonably likely to could adversely affect the attorney-client privilege between the Company and its counsel, result in disclosure of trade secrets counsel or highly confidential information, create a competitive harm or competitive disadvantage, or relates to subject matter in which Transhuman or CRS may have would be a conflict of interestinterest between such RA Capital Observer and the Company. (c) At any time that Deep Track does not have a representative on the Board, the Company shall allow one representative of Deep Track, for so long as Deep Track owns not less than 543,283 shares of Series E Preferred Stock (subject to adjustment for stock splits, stock dividends, combinations, reclassifications or the like), to attend all meetings of the Board in a nonvoting observer capacity (the “Deep Track Observer”). The Company shall give the Deep Track Observer copies of all notices, minutes, consents, and other materials that it provides to its directors at the same time and in the same manner as provided to the Board. The Deep Track Observer shall agree to hold in confidence and trust and to act in a fiduciary manner with respect to all information so provided. The Company reserves the right to withhold any information and to exclude the Deep Track Observer from any meeting or portion thereof if Transhuman, CRS the Board reasonably believes that access to such information or their representative is attendance at such meeting could adversely affect the attorney-client privilege between the Company and its counsel or would be a Competitorconflict of interest between such Deep Track Observer and the Company.

Appears in 1 contract

Sources: Investors’ Rights Agreement (Carmot Therapeutics Inc.)

Observer Rights. (a) As long as any shares of Preferred Stock are outstanding (as adjusted for stock splits15.2.1 During the Term, stock combinations, stock dividends and the like), the Company shall invite a representative of Collage Venture Partners, LLC, a Florida limited liability company (the “Placement Agent”), initially ▇Lockheed M▇▇▇▇▇ ▇▇▇▇▇▇▇, shall be entitled to designate one observer (the “Board Observer”) to attend all meetings any regular meeting (a “BOD Meeting”) of the Terran Board of Directors in a nonvoting observer capacity and(or, in this respecteach case, any relevant committees thereof), except that the Board Observer shall give not be entitled to vote on matters presented to or discussed by the Terran Board (or any relevant committee thereof) at any such representative copies meetings. The Board Observer shall be timely notified of the time and place of any BOD Meetings and will be given written notice of all notices, minutes, consents, and other materials that it provides proposed actions to be taken by the Terran Board (or any relevant committee thereof) as if the Board Observer were a member thereof. Such notice shall describe in reasonable detail the nature and substance of Directors; provided, however, that the matters to be discussed and/or voted upon at such representative meeting (or the proposed actions to be taken by written consent without a meeting). The Board Observer shall agree to hold in confidence all information so provided; and provided further, that the Company reserves have the right to withhold receive all information provided to the members of the Terran Board or any information and to exclude such representative from similar group performing an executive oversight or similar function (or any meeting relevant committee thereof) of the Company in anticipation of or portion thereof if access to such information or attendance at such meeting would be reasonably likely (regular or special and whether telephonic or otherwise), in addition to adversely affect copies of the attorney-client privilege between records of the Company proceedings or minutes of such meeting, when provided to the members, and its counselthe Board Observer shall keep such materials and information confidential in accordance with Section 12.07 of the Purchase Agreement (for the avoidance of doubt, result in disclosure of trade secrets or highly confidential information, create a competitive harm or competitive disadvantage, or relates to subject matter in which the Placement Agent may have a conflict of interest, or if the Placement Agent or its representative is a Competitor. (b) In the event that ▇.▇. ▇▇Lockheed M▇▇▇▇▇ (“▇▇. ▇▇▇▇▇▇▇”) is not elected shall be entitled to receive any such materials and information from the Board Observer as an Affiliate of the Series B Director (as defined Board Observer in the Voting Agreement) and so long as Transhuman Capital, LLC, a Delaware limited liability company (“Transhuman”) and CRS Capital, LLC, a Michigan limited liability company (“CRS”), together accordance with their Affiliates, own at least 1,000,000 shares Section 12.07 of Series B Preferred Stock purchased under the Purchase Agreement (as adjusted and shall keep such information confidential in accordance therewith). The Company shall reimburse the Board Observer for stock splits, stock combinations, stock dividends all reasonable out-of-pocket costs and expenses incurred in connection with its participation in any such BOD Meeting. 15.2.2 Notwithstanding the like)foregoing, the Company shall invite ▇▇. ▇▇may exclude the Board Observer from access to any material or meeting or portion thereof if: (i) the Terran Board concludes in good faith, upon advice of the Company’s counsel, that such exclusion is necessary to preserve the attorney-client or work product privilege between the Company or any of its Affiliates and its counsel; (ii) such portion of a meeting is an executive session limited solely to independent director members of the Terran Board, independent auditors and/or legal counsel, as the Terran Board may designate and such limitation is reasonably necessary with respect to the applicable matters; or (iii) such exclusion is necessary to avoid a conflict of interest between the Company on the one hand and Lockheed M▇▇▇▇▇ on the other. 15.2.3 The Board Observer shall be entitled to attend all meetings the same rights to travel, accommodation and other incidental expense reimbursement as the members of the Terran Board. The Company acknowledges and agrees that the foregoing right to reimbursement of expenses constitutes a third-party right extended to the Board Observer by the Company and does not constitute a right to reimbursement of expenses as a result of the Board Observer serving as a director, officer, employee or agent of Directors in a nonvoting observer capacity and, in this respect, shall give such representative copies of all notices, minutes, consents, and other materials that it provides to the Board of Directors; provided, however, that such representative shall agree to hold in confidence all information so provided; and provided further, that the Company reserves the right to withhold any information and to exclude such representative from any meeting or portion thereof if access to such information or attendance at such meeting would be reasonably likely to adversely affect the attorney-client privilege between the Company and its counsel, result in disclosure of trade secrets or highly confidential information, create a competitive harm or competitive disadvantage, or relates to subject matter in which Transhuman or CRS may have a conflict of interest, or if Transhuman, CRS or their representative is a CompetitorCompany.

Appears in 1 contract

Sources: Strategic Cooperation Agreement (Terran Orbital Corp)

Observer Rights. (a) As long as Bayer owns any shares of Preferred Stock are outstanding (as adjusted for stock splits, stock combinations, stock dividends and the likeor Common Stock issued upon conversion thereof), the Company shall invite a representative of Collage Venture Partners, LLC, a Florida limited liability company (the “Placement Agent”), initially ▇▇▇▇▇▇ ▇▇▇▇▇▇▇, Bayer to attend all non-executive session meetings of the Board (and of Directors each committee of the Board, if any) in a nonvoting observer capacity and, in this respect, shall give such representative copies of all notices, minutes, consents, and other materials that it provides to its directors at the Board of Directorssame time and in the same manner as provided to such directors; provided, however, that (i) such representative shall agree to hold in confidence and trust with respect to all information so provided; and provided further, that (ii) the Company reserves the right to withhold any information and to exclude such representative from any meeting or portion thereof if access to such information or attendance at such meeting would be reasonably likely to could adversely affect the attorney-client privilege between the Company and its counsel, counsel or result in disclosure of trade secrets or highly confidential information, create a competitive harm or competitive disadvantage, or relates to subject matter in which the Placement Agent may have a conflict of interest, or if the Placement Agent or its representative is a Competitor. (b) In the event that ▇.▇. ▇▇▇▇▇▇▇ (“▇▇. ▇▇▇▇▇▇▇”) is not elected to the Board as the Series B Director (as defined in the Voting Agreement) and so As long as Transhuman Capital, LLC, a Delaware limited liability company (“Transhuman”) and CRS Capital, LLC, a Michigan limited liability company (“CRS”), together with their Affiliates, own at least 1,000,000 Agent owns any shares of Series B Preferred Stock purchased under the Purchase Agreement (as adjusted for stock splits, stock combinations, stock dividends and the likeor Common Stock issued upon conversion thereof), the Company shall invite ▇▇. ▇▇▇▇▇▇▇ a representative of Agent to attend all non-executive session meetings of the Board (and of Directors each committee of the Board, if any) in a nonvoting observer capacity and, in this respect, shall give such representative copies of all notices, minutes, consents, and other materials that it provides to its directors at the Board of Directorssame time and in the same manner as provided to such directors; provided, however, that (i) such representative shall agree to hold in confidence and trust with respect to all information so provided; and provided further, that (ii) the Company reserves the right to withhold any information and to exclude such representative from any meeting or portion thereof if access to such information or attendance at such meeting would be reasonably likely to could adversely affect the attorney-client privilege between the Company and its counsel, counsel or result in disclosure of trade secrets or highly confidential information, create a competitive harm or competitive disadvantage, or relates to subject matter in which Transhuman or CRS may have a conflict of interest. (c) As long as Arix owns any shares of Preferred Stock (or Common Stock issued upon conversion thereof), the Company shall invite a representative of Arix to attend all non-executive session meetings of the Board (and of each committee of the Board, if any) in a nonvoting observer capacity and, in this respect, shall give such representative copies of all notices, minutes, consents, and other materials that it provides to its directors at the same time and in the same manner as provided to such directors; provided, however, that (i) such representative shall agree to hold in confidence and trust with respect to all information so provided; and (ii) the Company reserves the right to withhold any information and to exclude such representative from any meeting or portion thereof if Transhumanaccess to such information or attendance at such meeting could adversely affect the attorney-client privilege between the Company and its counsel or result in disclosure of trade secrets or a conflict of interest. (d) As long as a Janus Investor owns any shares of Preferred Stock (or Common Stock issued upon conversion thereof), CRS the Company shall invite a representative of Janus to attend all non-executive session meetings of the Board (and of each committee of the Board, if any) in a nonvoting observer capacity and, in this respect, shall give such representative copies of all notices, minutes, consents, and other materials that it provides to its directors at the same time and in the same manner as provided to such directors; provided, however, that (i) such representative shall agree to hold in confidence and trust with respect to all information so provided; and (ii) the Company reserves the right to withhold any information and to exclude such representative from any meeting or their portion thereof if access to such information or attendance at such meeting could adversely affect the attorney-client privilege between the Company and its counsel or result in disclosure of trade secrets or a conflict of interest. (e) As long as RTW owns any shares of Preferred Stock (or Common Stock issued upon conversion thereof), the Company shall invite a representative is of RTW to attend all non-executive session meetings of the Board (and of each committee of the Board, if any) in a Competitornonvoting observer capacity and, in this respect, shall give such representative copies of all notices, minutes, consents, and other materials that it provides to its directors at the same time and in the same manner as provided to such directors; provided, however, that (i) such representative shall agree to hold in confidence and trust with respect to all information so provided; and (ii) the Company reserves the right to withhold any information and to exclude such representative from any meeting or portion thereof if access to such information or attendance at such meeting could adversely affect the attorney-client privilege between the Company and its counsel or result in disclosure of trade secrets or a conflict of interest. (f) As long as Perceptive owns any shares of Preferred Stock (or Common Stock issued upon conversion thereof), the Company shall invite a representative of Perceptive to attend all non-executive session meetings of the Board (and of each committee of the Board, if any) in a nonvoting observer capacity and, in this respect, shall give such representative copies of all notices, minutes, consents, and other materials that it provides to its directors at the same time and in the same manner as provided to such directors; provided, however, that (i) such representative shall agree to hold in confidence and trust with respect to all information so provided; and (ii) the Company reserves the right to withhold any information and to exclude such representative from any meeting or portion thereof if access to such information or attendance at such meeting could adversely affect the attorney-client privilege between the Company and its counsel or result in disclosure of trade secrets or a conflict of interest. (g) As long as ▇▇▇▇▇▇▇▇▇ owns any shares of Preferred Stock (or Common Stock issued upon conversion thereof), the Company shall invite a representative of ▇▇▇▇▇▇▇▇▇ to attend all non-executive session meetings of the Board (and of each committee of the Board, if any) in a nonvoting observer capacity and, in this respect, shall give such representative copies of all notices, minutes, consents, and other materials that it provides to its directors at the same time and in the same manner as provided to such directors; provided, however, that (i) such representative shall agree to hold in confidence and trust with respect to all information so provided; and (ii) the Company reserves the right to withhold any information and to exclude such representative from any meeting or portion thereof if access to such information or attendance at such meeting could adversely affect the attorney-client privilege between the Company and its counsel or result in disclosure of trade secrets or a conflict of interest. (h) As long as HBM owns any shares of Preferred Stock (or Common Stock issued upon conversion thereof), the Company shall invite a representative of HBM to attend all non-executive session meetings of the Board (and of each committee of the Board, if any) in a nonvoting observer capacity and, in this respect, shall give such representative copies of all notices, minutes, consents, and other materials that it provides to its directors at the same time and in the same manner as provided to such directors; provided, however, that (i) such representative shall agree to hold in confidence and trust with respect to all information so provided; and (ii) the Company reserves the right to withhold any information and to exclude such representative from any meeting or portion thereof if access to such information or attendance at such meeting could adversely affect the attorney-client privilege between the Company and its counsel or result in disclosure of trade secrets or a conflict of interest. (i) As long as RA Capital owns any shares of Preferred Stock (or Common Stock issued upon conversion thereof), the Company shall invite a representative of RA Capital to attend all non-executive session meetings of the Board (and of each committee of the Board, if any) in a nonvoting observer capacity and, in this respect, shall give such representative copies of all notices, minutes, consents, and other materials that it provides to its directors at the same time and in the same manner as provided to such directors; provided, however, that (i) such representative shall agree to hold in confidence and trust with respect to all information so provided; and (ii) the Company reserves the right to withhold any information and to exclude such representative from any meeting or portion thereof if access to such information or attendance at such meeting could adversely affect the attorney-client privilege between the Company and its counsel or result in disclosure of trade secrets or a conflict of interest. (j) As long as BVF owns any shares of Preferred Stock (or Common Stock issued upon conversion thereof), the Company shall invite a representative of BVF to attend all non-executive session meetings of the Board (and of each committee of the Board, if any) in a nonvoting observer capacity and, in this respect, shall give such representative copies of all notices, minutes, consents, and other materials that it provides to its directors at the same time and in the same manner as provided to such directors; provided, however, that (i) such representative shall agree to hold in confidence and trust with respect to all information so provided; and (ii) the Company reserves the right to withhold any information and to exclude such representative from any meeting or portion thereof if access to such information or attendance at such meeting could adversely affect the attorney-client privilege between the Company and its counsel or result in disclosure of trade secrets or a conflict of interest. (k) As long as Ridgeback owns any shares of Preferred Stock (or Common Stock issued upon conversion thereof), the Company shall invite a representative of Ridgeback to attend all non-executive session meetings of the Board (and of each committee of the Board, if any) in a nonvoting observer capacity and, in this respect, shall give such representative copies of all notices, minutes, consents, and other materials that it provides to its directors at the same time and in the same manner as provided to such directors; provided, however, that (i) such representative shall agree to hold in confidence and trust with respect to all information so provided; and (ii) the Company reserves the right to withhold any information and to exclude such representative from any meeting or portion thereof if access to such information or attendance at such meeting could adversely affect the attorney-client privilege between the Company and its counsel or result in disclosure of trade secrets or a conflict of interest.

Appears in 1 contract

Sources: Investors’ Rights Agreement (Pyxis Oncology, Inc.)

Observer Rights. (a) As long as any Highland Capital Partners 9 Limited Partnership, Highland Capital Partners 9-B Limited Partnership, Highland Entrepreneurs’ Fund 9 Limited Partnership and/or their affiliates (collectively, “Highland Capital Partners”) owns shares of Preferred Stock are outstanding (as adjusted for stock splits, stock combinations, stock dividends and the likeor shares of Common Stock issued upon conversion thereof), the Company shall invite a representative of Collage Venture Partners, LLC, a Florida limited liability company (the “Placement Agent”), initially ▇▇▇▇▇▇ ▇▇▇▇▇▇▇, Highland Capital Partners to attend all meetings of the its Board of Directors in a nonvoting observer capacity and, in this respect, shall give such representative copies of all notices, minutes, consents, and other materials that it provides to its directors at the Board of Directorssame time and in the same manner as provided to such directors; provided, however, that such representative shall agree to hold in confidence and trust with respect to all information so provided, except that such representative may provide such information to Highland Capital Partners for purposes of monitoring its investment in the Company; and provided further, further that the Company reserves the right to withhold any information and to exclude such representative from any meeting or portion thereof if if, upon advice of counsel to the Company, access to such information or attendance at such meeting would be reasonably likely to adversely affect the attorney-client privilege between the Company and its counsel, counsel or result in the disclosure of trade secrets or highly confidential information, create a competitive harm or competitive disadvantage, or relates to subject matter in which the Placement Agent may have a conflict of interest, or if the Placement Agent or its representative is a Competitor. (b) In the event that ▇.▇. ▇▇▇▇▇▇▇ (“▇▇. ▇▇▇▇▇▇▇”) is not elected to the Board as the Series B Director (as defined in the Voting Agreement) and so As long as Transhuman Capital, LLC, a Delaware limited liability company (“Transhuman”) and CRS Capital, LLC, a Michigan limited liability company (“CRS”), together with their Affiliates, own at least 1,000,000 i Ventures and/or its affiliates owns shares of Series B Preferred Stock purchased under the Purchase Agreement (as adjusted for stock splits, stock combinations, stock dividends and the likeor shares of Common Stock issued upon conversion thereof), the Company shall invite ▇▇. ▇▇▇▇▇▇▇ a representative of i Ventures to attend all meetings of the its Board of Directors in a nonvoting observer capacity and, in this respect, shall give such representative copies of all notices, minutes, consents, and other materials that it provides to its directors at the Board of Directorssame time and in the same manner as provided to such directors; provided, however, that such representative shall agree to hold in confidence and trust with respect to all information so provided, except that such representative may provide such information to i Ventures for purposes of monitoring its investment in the Company; and provided further, further that the Company reserves the right to withhold any information and to exclude such representative from any meeting or portion thereof if if, upon advice of counsel to the Company, access to such information or attendance at such meeting would be reasonably likely to adversely affect the attorney-client privilege between the Company and its counsel, counsel or result in the disclosure of trade secrets or highly confidential information, create a competitive harm or competitive disadvantage, or relates to subject matter in which Transhuman or CRS may have a conflict of interest. (c) As long as ▇▇▇▇▇ Capital Fund II, L.P. (“▇▇▇▇▇”) and/or its affiliates owns shares of Series C Preferred Stock (or if Transhumanshares of Common Stock issued upon conversion thereof), CRS the Company shall invite a representative of ▇▇▇▇▇ to attend all meetings of its Board in a nonvoting observer capacity and, in this respect, shall give such representative copies of all notices, minutes, consents, and other materials that it provides to its directors at the same time and in the same manner as provided to such directors; provided, however, that such representative shall agree to hold in confidence and trust with respect to all information so provided, except that such representative may provide such information to ▇▇▇▇▇ for purposes of monitoring its investment in the Company; and provided further that the Company reserves the right to withhold any information and to exclude such representative from any meeting or portion thereof if, upon advice of counsel to the Company, access to such information or attendance at such meeting would adversely affect the attorney-client privilege between the Company and its counsel or result in the disclosure of trade secrets or a conflict of interest. (d) As long as any ▇. ▇▇▇▇ Price Investor owns shares of Preferred Stock (or shares of Common Stock issued upon conversion thereof), the Company shall invite a representative of ▇. ▇▇▇▇ Price to attend all meetings of its Board in a nonvoting observer capacity and, in this respect, shall give such representative copies of all notices, minutes, consents, and other materials that it provides to its directors at the same time and in the same manner as provided to such directors (including with respect to all committees, including executive sessions); provided, however, that such representative shall agree to hold in confidence and trust with respect to all information so provided, except that such representative may provide such information to the ▇. ▇▇▇▇ Price Investors for purposes of monitoring their investment in the Company; and provided further that the Company reserves the right to withhold any information and to exclude such representative is from any meeting or portion thereof if, upon advice of counsel to the Company, access to such information or attendance at such meeting would adversely affect the attorney-client privilege between the Company and its counsel or result in the disclosure of trade secrets or a Competitorconflict of interest. (e) As long as Durable owns shares of Preferred Stock (or shares of Common Stock issued upon conversion thereof), the Company shall invite a representative of Durable to attend all meetings of its Board in a nonvoting observer capacity and, in this respect, shall give such representative copies of all notices, minutes, consents, and other materials that it provides to its directors at the same time and in the same manner as provided to such directors (including with respect to all committees, including executive sessions); provided, however, that such representative shall agree to hold in confidence and trust with respect to all information so provided, except that such representative may provide such information to Durable for purposes of monitoring their investment in the Company; and provided further that the Company reserves the right to withhold any information and to exclude such representative from any meeting or portion thereof if, upon advice of counsel to the Company, access to such information or attendance at such meeting would adversely affect the attorney-client privilege between the Company and its counsel or result in the disclosure of trade secrets or a conflict of interest.

Appears in 1 contract

Sources: Investors’ Rights Agreement (Xometry, Inc.)

Observer Rights. (a) As long as any Sectoral owns at least 50% of the (i) shares of Series C-1 Preferred Stock are outstanding and Series C-2 Preferred Stock that it purchased pursuant to that certain Series C Stock Purchase Agreement, dated as of April 28, 2022 (including shares of Class A Common Stock issued upon conversion of Series C-1 Preferred Stock and Series C-2 Preferred Stock) and (ii) shares of Series C-3 Preferred Stock that it purchased pursuant to that certain Series C-3 Purchase Agreement, dated as adjusted for stock splitsof December 22, stock combinations, stock dividends and the like2022 (including shares of Class A Common Stock issued upon conversion of Series C-3 Preferred Stock), the Company shall invite a representative of Collage Venture Partners, LLC, a Florida limited liability company (the “Placement Agent”), initially ▇▇▇▇▇▇ ▇▇▇▇▇▇▇, Sectoral to attend all meetings of the Board of Directors in a nonvoting observer capacity and, in this respect, (the “Sectoral Board Observer”). The Company shall give such representative provide the Sectoral Board Observer with copies of all notices, minutes, consents, consents and other materials that it the Company provides its directors at any such meeting at the same time and in the same manner as provided to the Board of Directorssuch director; provided, however, that such representative the Sectoral Board Observer shall agree to hold in confidence all information so provided; provided further that Section 3.5 of this Agreement shall apply to any information so provided to the Sectoral Board Observer, mutatis mutandis; provided, further, the Company reserves the right to withhold any information and to exclude the Sectoral Board Observer from any meeting or portion thereof if: (i) the Company believes it is reasonably necessary to preserve attorney-client privilege between the Company and its counsel; (ii) access to such information or attendance at such meeting could result in disclosure of trade secrets; or (iii) access to such information or attendance at such meeting could result in a conflict of interest between the Sectoral Board Observer and/or Affiliates of the Sectoral Board Observer and the Company or its counsel. The Company shall in good faith endeavor to ensure that meetings of the Board or committees thereof are conducted in such a manner as to minimize those portions during which the Sectoral Board Observer shall be excluded, with a view of allowing the Sectoral Board Observer to attend and observe such meetings to the maximum extent possible. (b) As long as Columbia owns (i) at least 50% of the shares of Series B Preferred Stock that it purchased pursuant to that certain Series B Stock Purchase Agreement, dated as of March 12, 2021 (including shares of Class A Common Stock issued upon conversion of Series B Preferred Stock) and (ii) at least 50% of the shares of Series D Preferred Stock that it purchased pursuant to the Purchase Agreement (including shares of Class A Common Stock issued upon conversion of Series D Preferred Stock), the Company shall invite a representative of each of Columbia to attend all meetings of the Board in a nonvoting observer capacity (the “Columbia Board Observer”). The Company shall provide the Columbia Board Observer with copies of all notices, minutes, consents and other materials that the Company provides its directors at any such meeting at the same time and in the same manner as provided to such director; provided, however, that the Columbia Board Observer shall agree to hold in confidence all information so provided; provided, further, the Company reserves the right to withhold any information and to exclude the Columbia Board Observer from any meeting or portion thereof if: (i) the Company believes it is reasonably necessary to preserve attorney-client privilege between the Company and its counsel; (ii) access to such information or attendance at such meeting could result in disclosure of trade secrets; (iii) access to such information or attendance at such meeting could result in a conflict of interest between the Columbia Board Observer and/or Affiliates of the Columbia Board Observer and the Company or its counsel; or (iv) the Columbia Board Observer represents and/or is affiliated with a competitor of the Company. The Company shall in good faith endeavor to ensure that meetings of the Board or committees thereof are conducted in such a manner as to minimize those portions during which the Columbia Board Observer shall be excluded, with a view of allowing the Columbia Board Observer to attend and observe such meetings to the maximum extent possible. (c) As long as Alpha Wave owns at least 50% of (i) the shares of Series C-1 Preferred Stock and Series C-2 Preferred Stock that it purchased pursuant to that certain Series C Stock Purchase Agreement, dated as of April 28, 2022 (including shares of Class A Common Stock issued upon conversion of Series C-1 Preferred Stock and Series C-2 Preferred Stock) and (ii) shares of Series C-3 Preferred Stock that it purchased pursuant to that certain Series C-3 Purchase Agreement, dated as of December 22, 2022 (including shares of Class A Common Stock issued upon conversion of Series C-3 Preferred Stock), the Company shall invite a representative of Alpha Wave to attend all meetings of the Board in a nonvoting observer capacity (the “Alpha Wave Board Observer”). The Company shall provide the Alpha Wave Board Observer with copies of all notices, minutes, consents and other materials that the Company provides its directors at any such meeting at the same time and in the same manner as provided to such director; provided, however, that the Alpha Wave Board Observer shall agree to hold in confidence all information so provided; provided further that Section 3.5 of this Agreement shall apply to any information so provided to the Alpha Wave Board Observer, mutatis mutandis; provided, further, the Company reserves the right to withhold any information and to exclude the Alpha Wave Board Observer from any meeting or portion thereof if: (i) the Company believes it is reasonably necessary to preserve attorney-client privilege between the Company and its counsel; (ii) access to such information or attendance at such meeting could result in disclosure of trade secrets; (iii) access to such information or attendance at such meeting could result in a conflict of interest between the Alpha Wave Board Observer and/or Affiliates of the Alpha Wave Board Observer and the Company or its counsel. The Company shall in good faith endeavor to ensure that meetings of the Board or committees thereof are conducted in such a manner as to minimize those portions during which the Alpha Wave Board Observer shall be excluded, with a view of allowing the Alpha Wave Board Observer to attend and observe such meetings to the maximum extent possible. (d) As long as Shionogi owns at least 50% of the shares of Class B Common Stock and Class C Common Stock that it purchased pursuant to Purchase Agreement and that certain Common Stock Purchase Agreement, dated as of November 1, 2023 (including shares of Class A Common Stock issued upon conversion of the Class B Common Stock and the Class C Common Stock), the Company shall invite a representative of Shionogi to attend all meetings of the Board in a nonvoting observer capacity (the “Shionogi Board Observer”). The Company shall provide the Shionogi Board Observer with copies of all notices, minutes, consents and other materials that the Company provides its directors at any such meeting at the same time and in the same manner as provided to such director; provided, however, that the Shionogi Board Observer shall agree to hold in confidence all information so provided in accordance with Section 3.5; provided further that Section 3.5 of this Agreement shall apply to any information so provided to the Shionogi Board Observer, mutatis mutandis; provided, further, that the Company reserves the right to withhold any information and to exclude such representative the Shionogi Board Observer from any meeting or portion thereof if access if: (i) the Company believes it is reasonably necessary to such information or attendance at such meeting would be reasonably likely to adversely affect the preserve attorney-client privilege between the Company and its counsel, result in disclosure of trade secrets or highly confidential information, create a competitive harm or competitive disadvantage, or relates to subject matter in which the Placement Agent may have a conflict of interest, or if the Placement Agent or its representative is a Competitor. ; (bii) In the event that ▇.▇. ▇▇▇▇▇▇▇ (“▇▇. ▇▇▇▇▇▇▇”) is not elected to the Board as the Series B Director (as defined in the Voting Agreement) and so long as Transhuman Capital, LLC, a Delaware limited liability company (“Transhuman”) and CRS Capital, LLC, a Michigan limited liability company (“CRS”), together with their Affiliates, own at least 1,000,000 shares of Series B Preferred Stock purchased under the Purchase Agreement (as adjusted for stock splits, stock combinations, stock dividends and the like), the Company shall invite ▇▇. ▇▇▇▇▇▇▇ to attend all meetings of the Board of Directors in a nonvoting observer capacity and, in this respect, shall give such representative copies of all notices, minutes, consents, and other materials that it provides to the Board of Directors; provided, however, that such representative shall agree to hold in confidence all information so provided; and provided further, that the Company reserves the right to withhold any information and to exclude such representative from any meeting or portion thereof if access to such information or attendance at such meeting would be reasonably likely to adversely affect the attorney-client privilege between the Company and its counsel, could result in disclosure of trade secrets not already disclosed to Shionogi; or highly confidential information, create a competitive harm (iii) access to such information or competitive disadvantage, or relates to subject matter attendance at such meeting could result in which Transhuman or CRS may have a conflict of interestinterest between the Shionogi Board Observer and/or Affiliates of the Shionogi Board Observer and the Company or its counsel. The Company shall in good faith endeavor to ensure that meetings of the Board or committees thereof are conducted in such a manner as to minimize those portions during which the Shionogi Board Observer shall be excluded, or if Transhuman, CRS or their representative is with a Competitorview of allowing the Shionogi Board Observer to attend and observe such meetings to the maximum extent possible.

Appears in 1 contract

Sources: Investors’ Rights Agreement (Apnimed, Inc.)

Observer Rights. (a) As long as RTW Master Fund, Ltd., RTW Innovation Master Fund, Ltd. or any of their respective Affiliates (collectively, “RTW”) hold any shares of Preferred Stock are outstanding (as adjusted for stock splits, stock combinations, stock dividends and the likeor shares of Common Stock issued upon conversion thereof), the Company shall invite a representative of Collage Venture Partners, LLC, a Florida limited liability company (the “Placement Agent”), initially ▇▇▇▇▇▇ ▇▇▇▇▇▇▇, RTW to attend all meetings of the Board of Directors in a nonvoting observer capacity and, in this respect, shall give such representative copies of all notices, minutes, consents, consents and other materials that it provides to the Board of Directorsits directors; provided, however, that such representative shall agree to hold in confidence and trust with respect to all information so provided; and provided further, that the Company reserves the right to withhold any information and to exclude such representative from any meeting or portion thereof if access to such information or attendance at such meeting would be reasonably likely to could adversely affect the attorney-client privilege between the Company and its counsel, counsel or result in disclosure of trade secrets or highly confidential information, create a competitive harm or competitive disadvantage, or relates to subject matter in which the Placement Agent may have a direct conflict of interest, or if the Placement Agent such Investor or its representative is a CompetitorCompetitor of the Company. RTW shall be responsible to the Company for any disclosure or misuse of any information provided under this Subsection 3.4(a) that results from its representative’s failure to comply with this Subsection 3.4(a). (b) In the event that ▇.▇. ▇▇▇▇▇▇▇ As long as Apple Tree Partners IV, L.P. or any of its Affiliates (“▇▇. ▇▇▇▇▇▇▇ATP”) is not elected to the Board as the Series B Director (as defined in the Voting Agreement) and so long as Transhuman Capital, LLC, a Delaware limited liability company (“Transhuman”) and CRS Capital, LLC, a Michigan limited liability company (“CRS”), together with their Affiliates, own at least 1,000,000 holds any shares of Series B Preferred Stock purchased under the Purchase Agreement (as adjusted for stock splits, stock combinations, stock dividends and the like), or shares of Common Stock issued upon conversion thereof) the Company shall invite ▇▇. ▇▇▇▇▇▇▇ a representative of ATP to attend all meetings of the Board of Directors in a nonvoting observer capacity and, in this respect, shall give such representative copies of all notices, minutes, consents, consents and other materials that it provides to the Board of Directorsits directors; provided, however, that such representative shall agree to hold in confidence and trust with respect to all information so provided; and provided further, that the Company reserves the right to withhold any information and to exclude such representative from any meeting or portion thereof if access to such information or attendance at such meeting would be reasonably likely to could adversely affect the attorney-client privilege between the Company and its counsel, counsel or result in disclosure of trade secrets or highly confidential information, create a competitive harm or competitive disadvantage, or relates to subject matter in which Transhuman or CRS may have a conflict of interest, or if Transhuman, CRS such Investor or their its representative is a CompetitorCompetitor of the Company. ATP shall be responsible to the Company for any disclosure or misuse of any information provided under this Subsection 3.4(b) that results from its representative’s failure to comply with this Subsection 3.4(b). (c) As long as Cormorant Private Healthcare Fund I, LP or any of its Affiliates (“Cormorant”) holds any shares of Preferred Stock (or shares of Common Stock issued upon conversion thereof) the Company shall invite a representative of Cormorant to attend all meetings of the Board of Directors in a nonvoting observer capacity and, in this respect, shall give such representative copies of all notices, minutes, consents and other materials that it provides to its directors; provided, however, that such representative shall agree to hold in confidence and trust with respect to all information so provided; and provided further, that the Company reserves the right to withhold any information and to exclude such representative from any meeting or portion thereof if such information or attendance at such meeting could adversely affect the attorney-client privilege between the Company and its counsel or result in disclosure of trade secrets or a conflict of interest, or if such Investor or its representative is a Competitor of the Company. Cormorant shall be responsible to the Company for any disclosure or misuse of any information provided under this Section 3.4(c) that results from its representative’s failure to comply with this Subsection 3.4(c). (d) As long as RA Capital Healthcare Fund, L.P. or any of its Affiliates (“RA Capital”) holds any shares of Preferred Stock (or shares of Common Stock issued upon conversion thereof) the Company shall invite a representative of RA Capital to attend all meetings of the Board of Directors in a nonvoting observer capacity and, in this respect, shall give such representative copies of all notices, minutes, consents and other materials that it provides to its directors; provided, however, that such representative shall agree to hold in confidence and trust with respect to all information so provided; and provided further, that the Company reserves the right to withhold any information and to exclude such representative from any meeting or portion thereof if such information or attendance at such meeting could adversely affect the attorney-client privilege between the Company and its counsel or result in disclosure of trade secrets or a conflict of interest, or if such Investor or its representative is a Competitor of the Company. RA Capital shall be responsible to the Company for any disclosure or misuse of any information provided under this Section 3.4(d) that results from its representative’s failure to comply with this Subsection 3.4(d).

Appears in 1 contract

Sources: Investors’ Rights Agreement (Stoke Therapeutics, Inc.)

Observer Rights. (a) As long as 5AM Ventures continues to own beneficially any shares of Common Stock (including shares of Common Stock issued or issuable upon conversion of any class or series of Preferred Stock are outstanding (as adjusted for stock splits, stock combinations, stock dividends and the likeStock), the Company shall invite a representative of Collage Venture Partners, LLC, a Florida limited liability company 5AM Ventures (the “Placement Agent5AM Ventures Observer”), initially ▇▇▇▇▇▇ ▇▇▇▇▇▇▇, ) to attend all meetings of the Board of Directors and any committee thereof in a nonvoting observer capacity and, in this respect, capacity. The Company shall give such representative the 5AM Ventures Observer copies of all notices, minutes, consents, and other materials at the same time and in the same manner that it provides to the members of the Board of DirectorsDirectors or any of its committees; provided, however, that such representative 5AM Ventures shall, and shall agree to cause the 5AM Ventures Observer to, hold in confidence all information so provided in accordance with Subsection 3.5; and provided further, that the Company reserves the right to withhold any information and to exclude the 5AM Ventures Observer from any meeting or portion thereof if access to such information or attendance at such meeting could, upon the advice of counsel, adversely affect the attorney-client privilege between the Company and its counsel or result in disclosure of trade secrets or a conflict of interest. (b) As long as the Fidelity Investors continue to own beneficially any shares of Common Stock (including shares of Common Stock issued or issuable upon conversion of any class or series of Preferred Stock), the Company shall invite a representative of Fidelity (the “Fidelity Observer”) to attend all meetings of the Board of Directors and any committee thereof in a nonvoting observer capacity. The Company shall give the Fidelity Observer, or Fidelity if no Fidelity Observer is then designated by Fidelity, copies of all notices, minutes, consents, and other materials at the same time and in the same manner that it provides to the members of the Board of Directors or any of its committees; provided, however, that Fidelity shall, and shall cause the Fidelity Observer to, hold in confidence all information so provided in accordance with Subsection 3.5; and provided further, that the Company reserves the right to withhold any information and to exclude the Fidelity Observer from any meeting or portion thereof if access to such information or attendance at such meeting could, upon the advice of counsel, adversely affect the attorney-client privilege between the Company and its counsel or result in disclosure of trade secrets or a conflict of interest. (c) As long as Viridian continues to own beneficially any shares of Common Stock (including shares of Common Stock issued or issuable upon conversion of any class or series of Preferred Stock), the Company shall invite a representative of Viridian (the “Viridian Observer”) to attend all meetings of the Board of Directors and any committee thereof in a nonvoting observer capacity. The Company shall give the Viridian Observer copies of all notices, minutes, consents, and other materials at the same time and in the same manner that it provides to the members of the Board of Directors or any of its committees; provided, however, that Viridian shall, and shall cause the Viridian Observer to, hold in confidence and trust all information so provided; and provided further, that the Company reserves the right to withhold any information and to exclude such representative the Viridian Observer from any meeting or portion thereof if access to such information or attendance at such meeting would be reasonably likely to could, upon the advice of counsel, adversely affect the attorney-client privilege between the Company and its counsel, counsel or result in disclosure of trade secrets or highly confidential information, create a competitive harm or competitive disadvantage, or relates to subject matter in which the Placement Agent may have a conflict of interest, or if the Placement Agent or its representative is a Competitor. (bd) In As long as Venrock continues to own beneficially any shares of Common Stock (including shares of Common Stock issued or issuable upon conversion of any class or series of Preferred Stock), the event that ▇.▇. ▇Company shall invite two representatives of Venrock (the “Venrock Observers”), who shall initially be ▇▇▇▇▇▇ (“▇▇. ▇▇ and ▇▇▇▇▇▇ ▇▇▇▇▇▇▇”) is not elected to the Board as the Series B Director (as defined in the Voting Agreement) and so long as Transhuman Capital, LLC, a Delaware limited liability company (“Transhuman”) and CRS Capital, LLC, a Michigan limited liability company (“CRS”), together with their Affiliates, own at least 1,000,000 shares of Series B Preferred Stock purchased under the Purchase Agreement (as adjusted for stock splits, stock combinations, stock dividends and the like), the Company shall invite ▇▇. ▇▇▇▇▇▇▇ , to attend all meetings of the Board of Directors and any committee thereof in a nonvoting observer capacity and, in this respect, capacity. The Company shall give such representative the Venrock Observers copies of all notices, minutes, consents, and other materials at the same time and in the same manner that it provides to the members of the Board of DirectorsDirectors or any of its committees; provided, however, that such representative Venrock shall, and shall agree to cause the Venrock Observers to, hold in confidence and trust all information so provided; and provided further, that the Company reserves the right to withhold any information and to exclude such representative the Venrock Observers from any meeting or portion thereof if access to such information or attendance at such meeting would be reasonably likely to could, upon the advice of counsel, adversely affect the attorney-client privilege between the Company and its counsel, counsel or result in disclosure of trade secrets or highly confidential information, create a competitive harm or competitive disadvantage, or relates to subject matter in which Transhuman or CRS may have a conflict of interest. (e) As long as Fairmount continues to own beneficially any shares of Common Stock (including shares of Common Stock issued or issuable upon conversion of any class or series of Preferred Stock), the Company shall invite a representative of Fairmount (the “Fairmount Observer”) to attend all meetings of the Board of Directors and any committee thereof in a nonvoting observer capacity. The Company shall give the Fairmount Observer copies of all notices, minutes, consents, and other materials at the same time and in the same manner that it provides to the members of the Board of Directors or any of its committees; provided, however, that Fairmount shall, and shall cause the Fairmount Observer to, hold in confidence and trust all information so provided; and provided further, that the Company reserves the right to withhold any information and to exclude the Fairmount Observer from any meeting or portion thereof if Transhumanaccess to such information or attendance at such meeting could, CRS upon the advice of counsel, adversely affect the attorney-client privilege between the Company and its counsel or their result in disclosure of trade secrets or a conflict of interest. (f) As long as Tellus continues to own beneficially any shares of Common Stock (including shares of Common Stock issued or issuable upon conversion of any class or series of Preferred Stock), the Company shall invite a representative is of Tellus (the “Tellus Observer”) to attend all meetings of the Board of Directors and any committee thereof in a Competitornonvoting observer capacity. The Company shall give the Tellus Observer copies of all notices, minutes, consents, and other materials at the same time and in the same manner that it provides to the members of the Board of Directors or any of its committees; provided, however, that Tellus shall, and shall cause the Tellus Observer to, hold in confidence and trust all information so provided; and provided further, that the Company reserves the right to withhold any information and to exclude the Tellus Observer from any meeting or portion thereof if access to such information or attendance at such meeting could, upon the advice of counsel, adversely affect the attorney-client privilege between the Company and its counsel or result in disclosure of trade secrets or a conflict of interest.

Appears in 1 contract

Sources: Investors’ Rights Agreement (Magenta Therapeutics, Inc.)

Observer Rights. (a) As For so long as any shares of Preferred Stock are outstanding (as adjusted for stock splitsthe Original Qualifying Creditor Equityholders continue to hold, stock combinations, stock dividends and the like), the Company shall invite directly or indirectly through a representative of Collage Venture Partners, LLCBlockerco, a Florida limited liability company (number of Units equal to at least 50% of the “Placement Agent”)number of Units directly or indirectly held by the Original Qualifying Creditor Equityholders as of the Effective Date, initially ▇▇▇▇▇▇ ▇▇▇▇▇▇▇, a Majority of the Qualifying Creditor Equityholders shall have the right to attend all meetings of appoint one Observer to the Board of Directors of Holdco in a nonvoting observer capacity and, in this respect, accordance with the following: (i) A Majority of the Qualifying Creditor Equityholders shall give such representative copies of all notices, minutes, consents, and other materials that it provides submit to the Board of DirectorsDirectors of Holdco for its consideration a list of no fewer than three candidates (the “Candidate List”) to serve as the Observer, it being understood and agreed that such Majority of the Qualifying Creditor Equityholders shall include on the Candidate List only candidates who they reasonably believe the Board of Directors of Holdco will consider to be acceptable. Each candidate included on the Candidate List shall (A) not be an Affiliate of any Competitor, (B) be independent of Holdco within the meaning of Rule 303A.02 of the New York Stock Exchange Listed Company Manual or successor provision and without a direct or indirect material relationship with any of the Companies, and (C) be able to serve in the capacity of Observer without contravening any applicable laws or regulations, including Gaming Laws. (ii) The Board of Directors of Holdco shall use its reasonable efforts to screen the candidates appearing on the Candidate List (which screening shall consist of such interviews, background examinations and similar vetting processes as the Board of Directors of Holdco shall determine in its reasonable discretion) within 45 days following the submission of the Candidate List to the Board of Directors of Holdco by such Majority of the Qualifying Creditor Equityholders; provided, however, that such representative shall agree to hold Qualifying Creditor Equityholders and the candidates whose names appear on the Candidate List promptly comply with the reasonable requests made by the Board of Directors of Holdco in confidence all information so provided; and provided furtheraccordance with this subparagraph (ii). (iii) Following the completion of the aforementioned screening exercise, in the event that the Company reserves Board of Directors of Holdco determines in its sole discretion that any one or more of the screened candidates appearing on the Candidate List is acceptable to it, the Board of Directors of Holdco shall so advise such Majority of the Qualifying Creditor Equityholders, whereupon such Majority of the Qualifying Creditor Equityholders shall be entitled to exercise the right to appoint an Observer under this paragraph (a) with respect to any such screened candidate that the Board of Directors of Holdco has determined to be acceptable. (iv) In the event that the Board of Directors of Holdco determines in its sole discretion not to approve any candidate appearing on the Candidate List, it shall promptly so advise the Blockerco Equityholders and the Blockerco Equityholders shall thereafter supplement such Candidate List with additional candidates who satisfy the requirements set forth in subparagraph (i) above and resubmit the same to the Board of Directors of Holdco for screening in accordance with subparagraph (ii) above. (v) The Board of Directors of Holdco and the Qualifying Creditor Equityholders shall use their respective reasonable efforts to promptly complete the actions contemplated to be undertaken by each of them pursuant to this paragraph (a) in order to meet the timeframes set forth in subparagraph (ii) above and in order that the designation of an Observer pursuant to this paragraph (a) be completed within 90 days following the date on which the Board of Directors of Holdco receives the initial Candidate List. It is understood and agreed that the Board of Director’s exercise of its sole discretion as provided for in this paragraph (a) shall be carried out in good faith. (vi) In the event that the Qualifying Creditor Equityholders do not maintain ownership specified in this paragraph (a), such Observer shall no longer constitute an Observer and shall be automatically removed. In the event that the Observer appointed pursuant to this paragraph (a) resigns or is removed from such status and the Original Qualifying Creditor Equityholders continue to hold, directly or indirectly through Blockercos, a number of Units equal to at least 50% of the number of Units directly or indirectly through Blockercos held by the Original Qualifying Creditor Equityholders as of the Effective Date, then a Majority of the Qualifying Creditor Equityholders shall be entitled to exercise the rights granted pursuant to this paragraph (a) in the manner specified above in order to replace such Observer. (b) For so long as no DB Director on the Holdco Board of Directors is an officer or employee of Deutsche Bank or any Controlled Affiliate, a Majority of the DB Designated Equityholders shall have the right to appoint, remove and replace two Observers to the Holdco Board of Directors. At any time a Majority of the DB Designated Equityholders no longer have the right to appoint Observers pursuant to this paragraph (b), such Observers shall no longer constitute Observers and shall be automatically removed. (c) For so long as no DB Director on the Voteco Board of Directors, the New Propco Board of Directors or Sub Board is an officer or employee of Deutsche Bank or any Controlled Affiliate, a Majority of the DB Designated Equityholders shall have the right to appoint, remove and replace two Observers to the respective Board of Directors or Sub Board. At any time a Majority of the DB Designated Equityholders no longer have the right to appoint Observers pursuant to this paragraph (c), such Observers shall no longer constitute Observers and shall be automatically removed. (d) For so long as no JPM Director on the Holdco Board of Directors is an officer or employee of JPMorgan Chase Bank or any Controlled Affiliate, a Majority of the JPM Designated Equityholders shall have the right to appoint, remove and replace one Observer to the Holdco Board of Directors. At any time a Majority of the JPM Designated Equityholders no longer have the right to appoint an Observer pursuant to this paragraph (d), such Observer shall no longer constitute an Observer and shall be automatically removed. (e) For so long as no JPM Director on the Voteco Board of Directors, the New Propco Board of Directors or Sub Board is an officer or employee of JPMorgan Chase Bank or any Controlled Affiliate, a Majority of the JPM Designated Equityholders shall have the right to appoint, remove and replace one Observer to the respective Board of Directors or Sub Board. At any time a Majority of the JPM Designated Equityholders no longer have the right to appoint an Observer pursuant to this paragraph (e), such Observer shall no longer constitute an Observer and shall be automatically removed. (f) Each Observer shall be entitled to receive prior notice at substantially the same time such notice is given to the members of the applicable Board of Directors or Sub Board of any proposed action (including any proposed action by written consent) by each Board of Directors or Sub Board as to which it is entitled to Observer status, and to receive notice of any meeting of such Board of Directors or Sub Board (including telephonic or teleconferenced meetings) substantially concurrently with any notice given to the members of such Board of Directors or such Sub Board. Each Observer shall have the right to attend in person or by conference call and participate in all meetings of each Board of Directors and Sub Board to which it is entitled to Observer status (and any committee thereof) and to receive all materials distributed for or at any such meeting (including any meeting agenda or board package in the event such materials are prepared) and all other information and materials distributed to members of the applicable Board of Directors, Sub Board or committee, in each case, substantially concurrently with any such information or materials distributed to the members of the applicable Board of Directors, Sub Board or committee). No Observer shall be entitled to vote at a meeting of any Board of Directors or at the meeting of any Sub Board or receive compensation from the Company for services as an Observer (other than payment of expenses pursuant to Section 2.2). (g) The rights of each Observer and the obligations of the Companies set forth in this Section 2.13 shall be subject to the following: (i) such Observer shall have entered into a confidentiality agreement with the applicable Company or Companies in substantially the form attached hereto as Exhibit B; (ii) the applicable Company may withhold any information from such Observer, and to exclude such representative Observer from any meeting or portion thereof thereof, if access to such information or attendance at such meeting would could reasonably be reasonably likely expected, based on advice from outside counsel, to adversely affect the Company’s attorney-client privilege between or, in the Company and its counselcase of the Observer designated pursuant to paragraph (a), result in a disclosure of trade secrets or highly confidential information, create a competitive harm or competitive disadvantage, or relates to subject matter in which the Placement Agent may have a conflict of interest, or if the Placement Agent or its representative is a Competitor. ; (biii) In the event that ▇.▇. ▇▇▇▇▇▇▇ (“▇▇. ▇▇▇▇▇▇▇”) is not elected to the Board as the Series B Director (as defined in the Voting Agreementcase of the Observer designated pursuant to paragraph (a) and so long as Transhuman Capital, LLC, a Delaware limited liability company (“Transhuman”) and CRS Capital, LLC, a Michigan limited liability company (“CRS”), together with their Affiliates, own at least 1,000,000 shares of Series B Preferred Stock purchased under the Purchase Agreement (as adjusted for stock splits, stock combinations, stock dividends and the like)above, the Company shall invite ▇▇. ▇▇▇▇▇▇▇ to attend all meetings of the Board of Directors in a nonvoting observer capacity and, in this respect, shall give such representative copies of all notices, minutes, consents, and other materials that it provides to the Board of Directors; provided, however, that such representative shall agree to hold in confidence all information so provided; and provided further, that the Company reserves the right to Holdco may withhold any information from such Observer, and to exclude such representative Observer from any meeting or portion thereof thereof, if access to such information or attendance the information discussed at such meeting would (or portion thereof) is determined in the good faith discretion of the Holdco Board of Directors to be reasonably likely of competitive significance concerning Holdco or the other Companies; and (iv) the Observer designated by the Qualifying Creditor Equityholders may provide all materials distributed by Holdco to adversely affect such Observer in its capacity as Observer, redacted in form and substance satisfactory to the attorney-client privilege between Holdco Board of Directors to remove information determined, in the Company and its counseldiscretion of the Holdco Board of Directors, result in disclosure of to contain trade secrets or highly confidential information, create otherwise be of a competitive harm nature, to each Original Qualifying Creditor Equityholder that continues to hold, directly or competitive disadvantageindirectly through a Blockerco, a number of Units equal to at least 50% of the number of Units directly or relates to subject matter in which Transhuman or CRS may have a conflict indirectly held by such Original Qualifying Creditor Equityholder as of interest, or if Transhuman, CRS or their representative is a Competitorthe Effective Date.

Appears in 1 contract

Sources: Equityholders Agreement (Station Casinos LLC)

Observer Rights. (a) As long as any SV Life Sciences Fund IV, L.P. (“SV Life Sciences”) owns shares of Preferred Stock are outstanding (as adjusted for stock splits, stock combinations, stock dividends and the likeor Common Stock issued upon conversion thereof), the Company shall invite a representative of Collage Venture Partners, LLC, a Florida limited liability company (the “Placement Agent”), initially ▇▇▇▇▇▇ ▇▇▇▇▇▇▇, SV Life Sciences to attend all meetings of the its Board of Directors in a nonvoting observer capacity and, in this respect, shall give such representative copies of all notices, minutes, consents, and other materials that it provides to its directors at the Board of Directorssame time and in the same manner as provided to such directors; provided, however, that such representative shall agree to hold in confidence and trust and to act in a fiduciary manner with respect to all information so provided; and provided further, that the Company reserves the right to withhold any information and to exclude such representative from any meeting or portion thereof if access to such information or attendance at such meeting would be reasonably likely to could adversely affect the attorney-client privilege between the Company and its counsel, counsel or result in disclosure of trade secrets or highly confidential information, create a competitive harm or competitive disadvantage, or relates to subject matter in which the Placement Agent may have a conflict of interest, interest or if the Placement Agent or its representative is a Competitordisclosure of highly confidential proprietary information. (b) In the event that ▇.▇. ▇▇▇▇▇▇▇ As long as Clarus Lifesciences II, L.P. (“▇▇. ▇▇▇▇▇▇▇Clarus”) is not elected to the Board as the Series B Director (as defined in the Voting Agreement) and so long as Transhuman Capital, LLC, a Delaware limited liability company (“Transhuman”) and CRS Capital, LLC, a Michigan limited liability company (“CRS”), together with their Affiliates, own at least 1,000,000 owns shares of Series B Preferred Stock purchased under the Purchase Agreement (as adjusted for stock splits, stock combinations, stock dividends and the likeor Common Stock issued upon conversion thereof), the Company shall invite ▇▇. ▇▇▇▇▇▇▇ a representative of Clarus to attend all meetings of the its Board of Directors in a nonvoting observer capacity and, in this respect, shall give such representative copies of all notices, minutes, consents, and other materials that it provides to its directors at the Board of Directorssame time and in the same manner as provided to such directors; provided, however, that such representative shall agree to hold in confidence and trust and to act in a fiduciary manner with respect to all information so provided; and provided further, that the Company reserves the right to withhold any information and to exclude such representative from any meeting or portion thereof if access to such information or attendance at such meeting would be reasonably likely to could adversely affect the attorney-client privilege between the Company and its counsel, counsel or result in disclosure of trade secrets or highly confidential information, create a competitive harm or competitive disadvantage, or relates to subject matter in which Transhuman or CRS may have a conflict of interestinterest or disclosure of highly confidential proprietary information. (c) As long as Novo A/S owns shares of Preferred Stock (or Common Stock issued upon conversion thereof), the Company shall invite a representative of Novo A/S to attend all meetings of its Board of Directors in a nonvoting observer capacity and, in this respect, shall give such representative copies of all notices, minutes, consents, and other materials that it provides to its directors at the same time and in the same manner as provided to such directors; provided, however, that such representative shall agree to hold in confidence and trust and to act in a fiduciary manner with respect to all information so provided; and provided further, that the Company reserves the right to withhold any information and to exclude such representative from any meeting or portion thereof if Transhumanaccess to such information or attendance at such meeting could adversely affect the attorney-client privilege between the Company and its counsel or result in a conflict of interest or disclosure of highly confidential proprietary information. (d) As long as SV Life Sciences, CRS Novo A/S, HBM Healthcare Investments (Cayman) Ltd. (“HBM”) or their Clarus owns shares of Preferred Stock (or Common Stock issued upon conversion thereof), the Company shall invite a representative is of each of SV Life Sciences, Novo A/S, HBM or Clarus, as applicable, to attend all meetings of the Company’s scientific or other advisory boards in a Competitornonvoting observer capacity and, in this respect, shall give such representative copies of all notices, minutes, consents, and other materials that it provides to the members of such boards at the same time and in the same manner as provided to such members; provided, however, that such representative shall agree to hold in confidence and trust and to act in a fiduciary manner with respect to all information so provided; and provided further, that the Company reserves the right to withhold any information and to exclude such representative from any meeting or portion thereof if access to such information or attendance at such meeting could adversely affect the attorney-client privilege between the Company and its counsel or result in a conflict of interest or disclosure of highly confidential proprietary information.

Appears in 1 contract

Sources: Investors’ Rights Agreement (Ophthotech Corp.)

Observer Rights. (a) As long as any Trinity Ventures VIII, L.P. and its affiliates (“Trinity Ventures”) own not less than fifty percent (50%) of the shares of Series B Preferred Stock are outstanding (it originally purchased pursuant to the Series B Preferred Stock Purchase Agreement, dated as adjusted for stock splitsof August 4, stock combinations2003, stock dividends between the Company and each of the like)other parties thereto, the Company shall invite a representative of Collage Venture Partners, LLC, a Florida limited liability company (the “Placement Agent”), initially ▇▇▇▇▇▇ ▇▇▇▇▇▇▇, Trinity Ventures to attend all meetings of the its Board of Directors in a nonvoting observer capacity and, in this respect, shall give such representative copies of all notices, minutes, consents, consents and other materials that it provides to the Board of Directorsits directors; provided, however, that such representative shall agree to hold in confidence and trust and to act in a fiduciary manner with respect to all information so provided; and and, provided further, that the Company reserves the right to withhold any information and to exclude such representative from any meeting or portion thereof if access to such information or attendance at such meeting would be reasonably likely to could adversely affect the attorney-client privilege between the Company and its counsel, counsel or would result in disclosure of trade secrets or highly confidential information, create a competitive harm or competitive disadvantage, or relates to subject matter in which the Placement Agent may have a conflict of interest, such representative or if the Placement Agent such Investor or its representative is or is affiliated with a Competitordirect competitor of the Company. The Company agrees to reimburse such representative for its reasonable expenses incurred in connection with attending meetings of the Board of Directors. (b) In the event that ▇.▇. ▇▇▇▇▇▇▇ As long as WK Technology Fund and its affiliates (“▇▇. ▇▇▇▇▇▇▇WK Technology Fund”) is own not elected to less than fifty percent (50%) of the Board as the Series B Director (as defined in the Voting Agreement) and so long as Transhuman Capital, LLC, a Delaware limited liability company (“Transhuman”) and CRS Capital, LLC, a Michigan limited liability company (“CRS”), together with their Affiliates, own at least 1,000,000 shares of Series B C Preferred Stock it originally purchased under pursuant to the Series C Preferred Stock Purchase Agreement (Agreement, dated as adjusted for stock splitsof June 24, stock combinations2004, stock dividends between the Company and each of the like)other parties thereto, the Company shall invite ▇▇. ▇▇▇▇▇▇▇ a representative of WK Technology Fund to attend all meetings of the its Board of Directors in a nonvoting observer capacity and, in this respect, shall give such representative copies of all notices, minutes, consents, consents and other materials that it provides to the Board of Directorsits directors; provided, however, that such representative shall agree to hold in confidence and trust and to act in a fiduciary manner with respect to all information so provided; and and, provided further, that the Company reserves the right to withhold any information and to exclude such representative from any meeting or portion thereof if access to such information or attendance at such meeting would be reasonably likely to could adversely affect the attorney-client privilege between the Company and its counsel, counsel or would result in disclosure of trade secrets or highly confidential information, create a competitive harm or competitive disadvantage, or relates to subject matter in which Transhuman or CRS may have a conflict of interest, such representative or if Transhuman, CRS such Investor or their its representative is or is affiliated with a Competitordirect competitor of the Company. The Company agrees to reimburse such representative for its reasonable expenses incurred in connection with attending meetings of the Board of Directors. (c) As long as A▇▇▇▇ Capital Management, LLC and its affiliates (“A▇▇▇▇”) own not less than fifty percent (50%) of the shares of Series D Preferred Stock it originally purchased pursuant to the Series D Agreement, the Company shall invite a representative of A▇▇▇▇ to attend all meetings of its Board of Directors in a nonvoting observer capacity and, in this respect, shall give such representative copies of all notices, minutes, consents and other materials that it provides to its directors; provided, however, that such representative shall agree to hold in confidence and trust and to act in a fiduciary manner with respect to all information so provided; and, provided further, that the Company reserves the right to withhold any information and to exclude such representative from any meeting or portion thereof if access to such information or attendance at such meeting could adversely affect the attorney-client privilege between the Company and its counsel or would result in disclosure of trade secrets to such representative or if such Investor or its representative is or is affiliated with a direct competitor of the Company. The Company agrees to reimburse such representative for its reasonable expenses incurred in connection with attending meetings of the Board of Directors.

Appears in 1 contract

Sources: Investors’ Rights Agreement (Aruba Networks, Inc.)

Observer Rights. (a) As long as any shares Permit the Lender from time to time to designate one non-voting observer, who shall be reasonably acceptable to the Board of Preferred Stock are outstanding (as adjusted for stock splitsDirectors of the Borrower, stock combinations, stock dividends and to the like), Board of Directors of the Company shall invite a representative of Collage Venture Partners, LLC, a Florida limited liability company Borrower (the “Placement AgentBoard Observer”), initially ▇▇▇▇▇▇ ▇▇▇▇▇▇▇, ; give written notice to attend the Lender of all meetings of the Board of Directors in a nonvoting observer capacity andof the Borrower, in this respect, shall give such representative copies and of all notices, minutes, consents, and other materials that it provides action proposed to be taken by the Board of Directors of the Borrower by written consent, at the same time as notice thereof is given to such Board of Directors; with respect to all such meetings, permit the Board Observer to attend (either in person or, at the Board Observer’s option, by means of conference telephone call) any such meeting as a non-voting observer; and promptly pay or reimburse the Board Observer for all reasonable out-of-pocket expenses incurred by the Board Observer in attending such meeting (and to the extent not promptly paid or reimbursed, the Borrower hereby authorizes the Lender to charge such amounts to the Borrower’s revolving credit loan accounts with the Lender); provided, however, that such representative the Board Observer shall agree to hold in confidence (except that disclosure may be made as and to the extent permitted under Section 9.13 of the Loan Agreement) all confidential or proprietary information so providedprovided to the Board Observer in advance of any meeting, and all confidential or proprietary information discussed at any meeting at which the Board Observer is in attendance; and provided furtherfurther provided, that the Company Borrower reserves the right right, exercised in good faith, to withhold any information from the Board Observer and to exclude such representative the Board Observer from any meeting or portion thereof if and to the extent that (a) access to such information or attendance at such meeting or portion thereof would be reasonably likely to adversely affect the attorney-client privilege between the Company Borrower or the Board of Directors of the Borrower (or any committee of the Board of Directors) and its counsel, result in disclosure of trade secrets or highly confidential information, create a competitive harm or competitive disadvantage, or relates to subject matter in which the Placement Agent may have a conflict of interest, or if the Placement Agent or its representative is a Competitor. (b) In the event that ▇.▇. ▇▇▇▇▇▇▇ Lender is the subject matter under discussion, or (“▇▇. ▇▇▇▇▇▇▇”c) is not elected in the good faith judgment of counsel to the Board as Borrower, same is necessary to discharge the Series B Director (as defined in the Voting Agreement) and so long as Transhuman Capital, LLC, a Delaware limited liability company (“Transhuman”) and CRS Capital, LLC, a Michigan limited liability company (“CRS”), together with their Affiliates, own at least 1,000,000 shares of Series B Preferred Stock purchased under the Purchase Agreement (as adjusted for stock splits, stock combinations, stock dividends and the like), the Company shall invite ▇▇. ▇▇▇▇▇▇▇ to attend all meetings of the Board of Directors in a nonvoting observer capacity and, in this respect, shall give such representative copies of all notices, minutes, consents, and other materials that it provides to the Board of Directors; provided, however, that such representative shall agree to hold in confidence all information so provided; and provided further, that the Company reserves the right to withhold any information and to exclude such representative from any meeting or portion thereof if access to such information or attendance at such meeting would be reasonably likely to adversely affect the attorney-client privilege between the Company and its counsel, result in disclosure of trade secrets or highly confidential information, create a competitive harm or competitive disadvantage, or relates to subject matter in which Transhuman or CRS may have a conflict of interest, or if Transhuman, CRS or their representative is a Competitordirectors’ fiduciary duty.

Appears in 1 contract

Sources: Loan Agreement (Talon International, Inc.)

Observer Rights. (ai) As long as any SV Health Investors owns shares of Preferred Stock are outstanding (as adjusted for stock splits, stock combinations, stock dividends and the likeor Common Stock issued upon conversion thereof), the Company shall invite a representative of Collage Venture Partners, LLC, a Florida limited liability company (the “Placement Agent”), initially ▇▇▇▇▇▇ ▇▇▇▇▇▇▇, SV Health Investors to attend all meetings of the its Board of Directors in a nonvoting observer capacity and, in this respect, shall give such representative copies of all notices, minutes, consents, and other materials that it provides to its directors at the Board of Directorssame time and in the same manner as provided to such directors; provided, however, that such representative shall agree to hold in confidence and trust all information so provided; and provided provided, further, that the Company reserves the right to withhold any information and to exclude such representative from any meeting or portion thereof if access to such information or attendance at such meeting would be reasonably likely to could adversely affect the attorney-client privilege between the Company and its counsel, counsel or result in disclosure of trade secrets or highly confidential information, create a competitive harm or competitive disadvantage, or relates to subject matter in which the Placement Agent may have a conflict of interest, or if the Placement Agent or its representative is a Competitorsecrets. (bii) In the event that ▇.▇. ▇▇▇▇▇▇▇ (“▇▇. ▇▇▇▇▇▇▇”) is not elected to the Board as the Series B Director (as defined in the Voting Agreement) and so As long as Transhuman Capital, LLC, a Delaware limited liability company (“Transhuman”) and CRS Capital, LLC, a Michigan limited liability company (“CRS”), together with their Affiliates, own at least 1,000,000 Alta Partners owns shares of Series B Preferred Stock purchased under the Purchase Agreement (as adjusted for stock splits, stock combinations, stock dividends and the likeor Common Stock issued upon conversion thereof), the Company shall invite ▇▇. ▇▇▇▇▇▇▇ a representative of Alta Partners to attend all meetings of the its Board of Directors in a nonvoting observer capacity and, in this respect, shall give such representative copies of all notices, minutes, consents, and other materials that it provides to its directors at the Board of Directorssame time and in the same manner as provided to such directors; provided, however, that such representative shall agree to hold in confidence and trust all information so provided; and provided provided, further, that the Company reserves the right to withhold any information and to exclude such representative from any meeting or portion thereof if access to such information or attendance at such meeting would be reasonably likely to could adversely affect the attorney-client privilege between the Company and its counsel, counsel or result in disclosure of trade secrets secrets. (iii) As long as Skyline Ventures own shares of Preferred Stock (or highly confidential informationCommon Stock issued upon conversion thereof), create the Company shall invite a competitive harm representative of Skyline Partners to attend all meetings of its Board of Directors in a nonvoting observer capacity and, in this respect, shall give such representative copies of all notices, minutes, consents, and other materials that it provides to its directors at the same time and in the same manner as provided to such directors; provided, however, that such representative shall agree to hold in confidence and trust all information so provided; and provided, further, that the Company reserves the right to withhold any information and to exclude such representative from any meeting or competitive disadvantageportion thereof if access to such information or attendance at such meeting could adversely affect the attorney-client privilege between the Company and its counsel or result in disclosure of trade secrets. (iv) As long as Lilly Ventures own shares of Preferred Stock (or Common Stock issued upon conversion thereof), the Company shall invite a representative of Lilly Ventures to attend all meetings of its Board of Directors in a nonvoting observer capacity and, in this respect, shall give such representative copies of all notices, minutes, consents, and other materials that it provides to its directors at the same time and in the same manner as provided to such directors; provided, however, that such representative shall agree to hold in confidence and trust all information so provided; and provided, further, that the Company reserves the right to withhold any information and to exclude such representative from any meeting or relates portion thereof if access to subject matter such information or attendance at such meeting could adversely affect the attorney-client privilege between the Company and its counsel or result in which Transhuman or CRS may have a conflict disclosure of interest, or if Transhuman, CRS or their representative is a Competitortrade secrets.

Appears in 1 contract

Sources: Investors’ Rights Agreement (Sutro Biopharma Inc)

Observer Rights. (a) As long as any MRL Ventures owns not less than 600,000 shares of Preferred Stock are outstanding (as adjusted for stock splits, stock combinations, stock dividends and the like)or an equivalent amount of Common Stock issued upon conversion thereof , the Company shall invite a representative of Collage Venture Partners, LLC, a Florida limited liability company (the “Placement Agent”), initially ▇▇▇▇▇▇ ▇▇▇▇▇▇▇, MRL Ventures to attend all meetings of the Board of Directors in a nonvoting observer capacity and, in this respect, shall give such representative copies of all notices, minutes, consents, and other materials that it provides to the Board of Directorsits directors; provided, however, that such representative shall agree to hold in confidence and trust with respect to all information so providedprovided (in a manner consistent with the confidentiality obligations of a director of a Delaware corporation); and provided further, that the Company reserves the right to withhold any information and to exclude such representative from any meeting or portion thereof if access to such information or attendance at such meeting would be reasonably likely to could adversely affect the attorney-client privilege between the Company and its counsel, counsel or result in disclosure of trade secrets or highly confidential information, create a competitive harm or competitive disadvantage, or relates to subject matter in which the Placement Agent may have a conflict of interest, or if the Placement Agent such Investor or its representative is a Competitor. (b) In the event that ▇.▇. ▇▇▇▇▇▇▇ (“▇▇. ▇▇▇▇▇▇▇”) is not elected to the Board as the Series B Director (as defined in the Voting Agreement) and so As long as Transhuman Capital, LLC, a Delaware limited liability company (“Transhuman”) and CRS Capital, LLC, a Michigan limited liability company (“CRS”), together with their Affiliates, own at least 1,000,000 Hatteras Venture Partners owns not less than 600,000 shares of Series B Preferred Stock purchased under the Purchase Agreement (as adjusted for stock splits, stock combinations, stock dividends and the likeor an equivalent amount of Common Stock issued upon conversion thereof), the Company shall invite ▇▇. ▇▇▇▇▇▇▇ a representative of Hatteras Venture Partners to attend all meetings of the Board of Directors in a nonvoting observer capacity and, in this respect, shall give such representative copies of all notices, minutes, consents, and other materials that it provides to the Board of Directorsits directors; provided, however, that such representative shall agree to hold in confidence and trust with respect to all information so providedprovided (in a manner consistent with the confidentiality obligations of a director of a Delaware corporation); and provided further, that the Company reserves the right to withhold any information and to exclude such representative from any meeting or portion thereof if access to such information or attendance at such meeting would be reasonably likely to could adversely affect the attorney-client privilege between the Company and its counselcounsel or result in disclosure of trade secrets result in a conflict of interest, or if such Investor or its representative is a Competitor. (c) As long as Genzyme owns not less than 600,000 shares of Preferred Stock (or an equivalent amount of Common Stock issued upon conversion thereof ), the Company shall invite a representative of Sanofi Ventures to attend all meetings of the Board of Directors in a nonvoting observer capacity and, in this respect, shall give such representative copies of all notices, minutes, consents, and other materials that it provides to its directors; provided, however, that such representative shall agree to hold in confidence and trust with respect to all information so provided (in a manner consistent with the confidentiality obligations of a director of a Delaware corporation); and provided further, that the Company reserves the right to withhold any information and to exclude such representative from any meeting or portion thereof if access to such information or attendance at such meeting could adversely affect the attorney-client privilege between the Company and its counsel or result in disclosure of trade secrets or highly confidential information, create a competitive harm or competitive disadvantage, or relates to subject matter result in which Transhuman or CRS may have a conflict of interest, or if Transhuman, CRS such Investor or their its representative is a Competitor.

Appears in 1 contract

Sources: Investors’ Rights Agreement (Kymera Therapeutics, Inc.)

Observer Rights. (a) As ACOF shall have the right to designate an observer to the Board (the “ACOF Observer”) so long as ACOF, together with its Affiliates and Permitted Transferees, beneficially owns less than 5% and greater than 2% of the total Shares outstanding (calculated without reference to any shares of Preferred Capital Stock are outstanding issued or issuable on (other than shares issued as adjusted for stock splits, stock combinations, stock dividends and part of the likePre-Spin Recapitalization) or after the date of this Agreement), the Company . The ACOF Observer shall invite a representative of Collage Venture Partners, LLC, a Florida limited liability company (the “Placement Agent”), initially ▇▇▇▇▇▇ ▇▇▇▇▇▇▇, be permitted to attend all meetings each meeting of the Board or any committee thereof (including any executive sessions of Directors in a nonvoting observer capacity andthe Board), in this respect, shall give such representative copies of all notices, minutes, consents, and other materials that it provides but will not be entitled to vote on any matter submitted to the Board of Directors; providedor such committee thereof. Subject to any documents subject (as determined in good faith by the Board) to attorney/client privilege, however, that such representative the ACOF Observer shall agree be provided with the same notice and information given to hold in confidence all information so provided; and provided further, that the Company reserves the right Directors pursuant to withhold any information and to exclude such representative from any meeting or portion thereof if access to such information or attendance at such meeting would be reasonably likely to adversely affect the attorney-client privilege between the Company and its counsel, result in disclosure of trade secrets or highly confidential information, create a competitive harm or competitive disadvantage, or relates to subject matter in which the Placement Agent may have a conflict of interest, or if the Placement Agent or its representative is a CompetitorSection 3.3(c). (b) In ESL shall have the event that ▇.▇. ▇▇▇▇▇▇▇ (“▇▇. ▇▇▇▇▇▇▇”) is not elected right to designate an observer to the Board as (the Series B Director (as defined in the Voting Agreement“ESL Observer”) and so long as Transhuman Capital, LLC, a Delaware limited liability company (“Transhuman”) and CRS Capital, LLC, a Michigan limited liability company (“CRS”)ESL, together with their Affiliatesits Affiliates and Permitted Transferees, own at least 1,000,000 beneficially owns less than 5% and greater than 2% of the total Shares outstanding (calculated without reference to any shares of Series B Preferred Capital Stock purchased under issued or issuable on (other than shares issued as part of the Purchase Agreement (as adjusted for stock splits, stock combinations, stock dividends and Pre-Spin Recapitalization) or after the likedate of this Agreement), the Company . The ESL Observer shall invite ▇▇. ▇▇▇▇▇▇▇ be permitted to attend all meetings each meeting of the Board or any committee thereof (including any executive sessions of Directors in a nonvoting observer capacity andthe Board), in this respect, shall give such representative copies of all notices, minutes, consents, and other materials that it provides but will not be entitled to vote on any matter submitted to the Board or such committee thereof. Subject to any documents subject (as determined in good faith by the Board) to attorney/client privilege, the ESL Observer shall be provided with the same notice and information given to Directors pursuant to Section 3.3(c). (c) Notwithstanding anything to the contrary in this Agreement, if the Board or any committee thereof determines in good faith that exclusion of Directors; provided, however, that such representative shall agree an ACOF Observer or an ESL Observer is reasonably necessary in order (i) to hold in confidence all information so provided; and provided further, that preserve the attorney/client privilege of the Company reserves and/or its Subsidiaries (ii) to avoid disclosure that is prohibited by an agreement with a third party or that might cause information to no longer be a trade secret of the right Company and/or one of its Subsidiaries or (iii) to withhold any information and to exclude such representative from any meeting avoid a conflict of interest based on actual or portion thereof if access to such information expressly contemplated claims, defenses, disputes or attendance at such meeting would be reasonably likely to adversely affect the attorney-client privilege transactions between the Company or any of its Subsidiaries, on the one hand, and its counselACOF, result in disclosure ESL or any of trade secrets their respective Affiliates, on the other hand, then such ACOF Observer or highly confidential information, create ESL Observer (as applicable) shall be excluded from the portions of a competitive harm meeting of the Board or competitive disadvantage, or relates a committee thereof relating to subject such matter in which Transhuman or CRS may have a conflict of interest, or if Transhuman, CRS or their representative is a Competitorand shall not be provided any information that Directors otherwise receive with respect to such matter.

Appears in 1 contract

Sources: Stockholders’ Agreement (Orchard Supply Hardware Stores Corp)